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A B S T R A C T
Background
Cystic fibrosis is a multi-system disease characterised by the production of thick secretions causing recurrent pulmonary infection, often
with unusual bacteria. Intravenous antibiotics are commonly used in the treatment of acute deteriorations in symptoms (pulmonary
exacerbations); however, recently the assumption that exacerbations are due to increases in bacterial burden has been questioned.
Objectives
To establish if intravenous antibiotics for the treatment of pulmonary exacerbations in people with cystic fibrosis improve short- and
long-term clinical outcomes.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals
and conference abstract books. We also searched the reference lists of relevant articles and reviews and ongoing trials registers.
Date of last search of Cochrane trials register: 27 July 2015.
Selection criteria
Randomised controlled trials and the first treatment cycle of cross-over studies comparing intravenous antibiotics (given alone or in an
antibiotic combination) with placebo, inhaled or oral antibiotics for people with cystic fibrosis experiencing a pulmonary exacerbation.
Data collection and analysis
The authors assessed studies for eligibility and risk of bias and extracted data.
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Main results
We included 40 studies involving 1717 participants. The quality of the included studies was largely poor and, with a few exceptions,
these comprised of mainly small, inadequately reported studies.
When comparing treatment with a single antibiotic to a combined antibiotic regimen, those participants receiving a combination
of antibiotics experienced a greater improvement in lung function when considered as a whole group across a number of different
measurements of lung function, but with very low quality evidence. When limited to the four placebo-controlled studies (n = 214),
no difference was observed, again with very low quality evidence. With regard to the review’s remaining primary outcomes, there was
no effect upon time to next exacerbation and no studies in any comparison reported on quality of life. There were no effects on the
secondary outcomes weight or adverse effects. When comparing specific antibiotic combinations there were no significant differences
between groups on any measure. In the comparisons between intravenous and nebulised antibiotic or oral antibiotic (low quality
evidence), there were no significant differences between groups on any measure. No studies in any comparison reported on quality of
life.
Authors’ conclusions
The quality of evidence comparing intravenous antibiotics with placebo is poor. No specific antibiotic combination can be considered
to be superior to any other, and neither is there evidence showing that the intravenous route is superior to the inhaled or oral routes.
There remains a need to understand host-bacteria interactions and in particular to understand why many people fail to fully respond
to treatment.
P L A I N L A N G U A G E S U M M A R Y
The use of intravenous antibiotics to treat pulmonary exacerbations in people with cystic fibrosis
Review question
Do intravenous antibiotics (antibiotics given via a vein) given to treat ’flare ups’ of lung disease (pulmonary exacerbations) in people
with cystic fibrosis improve clinical outcomes in the short term and the long term?
Background
We wanted to evaluate the evidence for the current practice of using intravenous antibiotics to treat people with cystic fibrosis who
have a pulmonary exacerbation. We wanted to discover if it is better to give two antibiotics than just a single antibiotic and wanted to
consider if any particular antibiotic combination is better than any other. We also wanted to discover if intravenous antibiotics are any
better than inhaled or oral antibiotics in treating pulmonary exacerbations in people with cystic fibrosis.
Search date
We last searched for evidence on 27 July 2015.
Study characteristics
The review included 40 studies with 1717 people with cystic fibrosis. Studies compared intravenous antibiotics with placebo (dummy
drug with no active medication) and also one antibiotic compared to two antibiotics given together. Specific antibiotic combinations
were also compared as were intravenous antibiotics with antibiotics that were breathed in (inhaled) and antibiotics that were swallowed
(oral). The studies lasted from three to 15 days, although most of the studies lasted for two weeks.
Key results
In the comparison between those people who were given just one antibiotic and those who were given two, it appeared that those
receiving two antibiotics experienced a greater improvement in lung function, but when limited to only those studies that included
a dummy drug, we did not see any difference. There was no effect upon the amount of time until the next exacerbation, weight, or
adverse effects. No combination of antibiotics was any better than any other. The outcomes for people were the same irrespective of
whether they were treated by intravenous, oral or inhaled antibiotics. None of the studies reported on quality of life.
Quality of the evidence
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The quality of the included studies was often poor and many were not properly reported. Some studies included volunteers more than
once which made comparing treatments difficult. It was also often difficult to decide from the information given how well the studies
were carried out - particularly with respect to how volunteers were chosen and whether the volunteers or doctors could tell which
treatment they were being given.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Single versus combination IV antibiotics for pulmonary exacerbations in people with cystic fibrosis
Patient or population: people with cyst ic f ibrosis experiencing a pulmonary exacerbat ion
Settings: inpatient (hospital)
Intervention: single IV ant ibiot ic (with or without a placebo)
Comparison: combinat ion IV ant ibiot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Combination IV antibi-
otics
Single
IV antibiotics (with or
without placebo)
FEV1 (% predicted) ab-
solute change
Follow up: 7 - 14 days
The mean (range) abso-
lute change in FEV1 (%
predicted) in the control
group was 11.82% (8%
to 15%)
The mean absolute
change in FEV1 (% pre-
dicted) in the interven-
t ion group was
1.14% lower
(3.23 lower to 0.95
higher)
265 (6 studies)
(Bosso 1988; De
Boeck 1989; Hyatt
1981; Master 2001;
McLaughlin 1983;
Smith 1999)
⊕⊕©©
low1,2
The assumed risk rep-
resents the mean of
ef fect observed in the
combinat ion IV ant ibi-
ot ics group and the cor-
responding risk that of
the result of the meta-
analysis with respect to
the comparison group
receiving single IV an-
t ibiot ics (with or with-
out placebo)
Quality was determined
by downgrading by one
point based on part ici-
pants re-entering study
more than once and
so introducing bias;
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it was further down-
graded due to the low
numbers of events
FVC (% predicted) ab-
solute change
Follow up: 7 - 14 days
The mean absolute
change in FVC (% pre-
dicted) in the control
group was 11.70% (7%
to 15.4%)
The mean absolute
change in FVC (% pre-
dicted) in the interven-
t ion group was
1.37% lower
(4.56 lower to 1.81
higher)
146 (4 studies)
(Bosso 1988; Hyatt
1981; McLaughlin
1983; Smith 1999)
⊕⊕©©
low1,2
The assumed risk rep-
resents the mean of
ef fect observed in the
combinat ion IV ant ibi-
ot ics group and the cor-
responding risk that of
the result of the meta-
analysis with respect to
the comparison group
receiving single IV an-
t ibiot ics (with or with-
out placebo)
Quality was determined
by downgrading by one
point based on part ici-
pants re-entering study
more than once and
so introducing bias;
it was further down-
graded due to the low
numbers of events
Time to next exacerba-
t ion (weeks)
The mean time to
next exacerbat ion in the
control group was 24
weeks
The mean time to next
exacerbat ion in the in-
tervent ion group was
7.00 weeks lower (23.
67 lower to 9.67 higher)
34 (1 study) (
McLaughlin 1983)
⊕⊕©©
low1,2
The assumed risk rep-
resents the mean of
ef fect observed in the
combinat ion IV ant ibi-
ot ics group and the cor-
responding risk that of
the result of the meta-
analysis with respect to
the comparison group
receiving single IV an-
t ibiot ics (with or with-
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out placebo)
Quality was determined
by downgrading by one
point based on part ici-
pants re-entering study
more than once and
so introducing bias;
it was further down-
graded due to the low
numbers of events
Quality of lif e Not reported
* The authors calculated the assumed risk as the mean of the ef fect size of the control group in each study
The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; FEV1 : f orced expiratory volume at one second; FVC: f orced vital capacity; IV: intravenous
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level for risk of bias; the analysis did not account for mult iple observat ions f rom the same part icipants.
2 Downgraded one level due to the low numbers of events observed in the studies.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a multi-organ life-limiting condition in-
herited in an autosomally recessive manner. It is characterised by
viscid secretions of many organs, in particular the lungs and pan-
creas. In the lungs these viscid secretions interfere with the mech-
anisms responsible for clearing inhaled material, allowing oppor-
tunistic bacteria to establish infections. Important pathogens in-
clude Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus au-
reus (S.aureus), Haemophilus influenzae, and many others, with S.
aureus and P. aeruginosa being the most prevalent in childhood
and adulthood respectively (Cystic Fibrosis Foundation Patient
Registry 2011; Guss 2011). It is thought that early infection
with P. aeruginosamay be eradicated by antibiotics (Gibson 2003;
Langton Hewer 2009; Ratjen 2001), but eventually the infection
becomes chronic and can no longer be eradicated. Chronic infec-
tion causes persistent symptoms of cough and sputum production
and is associated with progressive loss of lung function (Ballmann
1998). In addition, people with CF experience pulmonary exacer-
bations, which are characterised by an increase in symptoms (Goss
2007) and reductions in lung function, weight and quality of life
(Britto 2002). The causes of these exacerbations are not known,
but it is suspected that they may be due, in part, to bacterial in-
fection. A standard definition of what constitutes a pulmonary ex-
acerbation has yet to be agreed, but there is reasonable consensus
that a pulmonary exacerbation usually consists of people with CF
reporting a decline in well-being largely due to respiratory symp-
toms that prompts the commencement of a course of antibiotics
(Bilton 2011).
Description of the intervention
Pulmonary exacerbations have long been treated with antibiotics
and this is currently the recommendation inEurope (Doring 2000)
and the USA (Flume 2009). An assumption underlying a corner-
stone of CF care is that pulmonary exacerbations are associated
with bacterial infection (in particular due to P. aeruginosa), leading
to the conclusion that these exacerbations should be treated with
antibiotics (Doring 2000).Observational data suggest that oral, in-
travenous (IV) and nebulised antibiotics are administered to treat
a pulmonary exacerbation (Wagener 2013). When IV antibiotics
are used, a combination of two or more different IV antibiotics
are recommended; however, the optimal duration of IV antibiotic
therapy is unknown (Flume 2009; Elphick 2014; Plummer 2013).
How the intervention might work
Although an accepted definition of what constitutes a pulmonary
exacerbation has yet to be developed, pulmonary exacerbations
are assumed to be caused (at least in part) by bacterial infection.
Antibiotics are administered in order to reduce the amount of bac-
teria in the lungs that are presumed to be responsible for much
of the decline in the individual’s clinical condition (Flume 2009).
These antibiotics may, or may not, reduce the amount of bacte-
ria in the lungs. There may be many different species of bacteria
present (Guss 2011) and these broad-spectrum antibiotics may
have variable activity against these bacteria. However, antibiotics
may themselves be associated with considerable morbidity includ-
ing selecting for antibiotic resistance (Rogues 2007) and causing
renal toxicity and ototoxicity (Bertenshaw 2007; Smyth 2014).
Prolonged courses of antibiotic treatment may also pose a signifi-
cant burden of treatment for people with CF to endure.
Why it is important to do this review
Pulmonary exacerbations are responsible for an accelerated decline
in lung function (de Boer 2011) and a significant proportion of
people experiencing a pulmonary exacerbation who are treated
with IV antibiotics, do not recover lung function to baseline (
Sanders 2010). Potential reasons for this include:
• the aetiology of the exacerbation (e.g. viral infection) and so
prevention is the main goal;
• the host (e.g. inflammation) so novel therapies might be
developed to modulate the immune system;
• factors related to the treatment, and so we must determine
optimal treatments (and routes of treatment) which can include
use of IV antibiotics.
Often, IV antibiotics are held to be the most effective form of
antibiotic delivery. We wished not only to determine the efficacy
of IV antibiotics in treating people with CF experiencing a pul-
monary exacerbation, but also to determine the comparative effec-
tiveness of the IV route compared against antibiotics administered
via oral or inhaled routes.
We have reviewed the current evidence that treating such exac-
erbations with IV antibiotics improves short-term and long-term
clinical outcomes in people with CF.
O B J E C T I V E S
To establish if IV antibiotics for the treatment of pulmonary exac-
erbations in people with CF improve short- and long-term clinical
outcomes.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We shall include randomised controlled trials (RCTs) and the first
treatment cycle of cross-over studies (seeUnit of analysis issues) in
people with CF experiencing a pulmonary exacerbation.
Types of participants
We will consider people with CF as diagnosed using the Cystic
Fibrosis Foundation consensus statement (Rosenstein 1998) of all
ages and all degrees of disease severity. There are no universally
agreed definitions for the diagnosis of a pulmonary exacerbation;
some criteria are restrictive (Fuchs 1994) (since modified), while
others only require an event needing hospitalisation and IV an-
tibiotics due to worsening respiratory signs and symptoms (Brody
2005). We will therefore consider all studies that explicitly aim to
trial an IV antibiotic for the treatment of a pulmonary exacerba-
tion.
Types of interventions
We shall compare:
• a single IV antibiotic versus placebo;
• a combination of IV antibiotics versus placebo;
• one regimen of IV antibiotics versus another IV regimen of
antibiotics (with or without placebo);
• an IV antibiotic regimen versus nebulised antibiotics; and
• an IV antibiotic regimen versus oral antibiotics.
Studies that exclusively compare different doses of the same an-
tibiotic will be excluded (post hoc change).
Types of outcome measures
Primary outcomes
1. Lung function
i) forced expiratory volume at one second (FEV1)
ii) forced vital capacity (FVC)
2. Time to next exacerbation (although as there is no agreed
definition of pulmonary exacerbations, we shall accept the
individual clinicians’ diagnosis, acknowledging the inherent
difficulties that this poses)
3. Quality of life (e.g. Cystic Fibrosis Questionnaire-Revised
(CFQ-R) (Quittner 2009))
Secondary outcomes
1. Symptom score using a validated tool (e.g. acute respiratory
illness checklist (ARIC), respiratory and systemic symptoms
questionnaire (RSS-Q))
2. Nutritional status
i) body mass index (BMI) (all measures)
ii) weight (all measures)
3. Adherence (all measures)
4. Mortality (CF-related and all causes)
5. Adverse effects
i) toxicity and allergy - e.g. idiosyncratic reaction,
allergy, decline in renal function
ii) microbiological - isolation of antibiotic resistant
strains, or new strains of bacteria
Search methods for identification of studies
Electronic searches
We identified relevant studies from the Group’s Cystic Fibrosis
Trials Register using the terms: antibiotics AND (intravenous OR
not stated) AND (acute treatment [pulmonary exacerbations] OR
unknown).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cystic Fibrosis
and Genetic Disorders Group Module.
Date of the latest search: 27 July 2015.
We also searched the clinical trials registers: ClinicalTrials.gov;
ISRCTN; and EudraCT for ongoing trials using the search terms:
cystic fibrosis AND antibiotics.
Date of the latest search: 02 July 2014.
Searching other resources
We searched the reference lists of all included studies to identify
other studies for potential inclusion.
Data collection and analysis
Selection of studies
One author (MH) reviewed the abstracts of studies identified by
the literature search and excluded studies that did not consider
the management of pulmonary exacerbations in CF with IV an-
tibiotics. Two investigators (MH, AP) independently considered
the full text reports of the remaining studies. They examined each
study for potential inclusion and for consideration of multiple
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reporting by comparing reports using author names, study loca-
tion, intervention details and date of the study as described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011a). They resolved any disagreement through discussion and
where necessary arbitration by the third author (PF).
Data extraction and management
Two authors (MH, AP) independently extracted the data from the
included studies on a separate study report form and compared
the output. They resolved any disagreement through discussion.
Where one paper presented data graphically, the authors extracted
the data they required using XYPLOT (a graphics-based computer
programme where data points may be extracted using the scale of
axes as reference points) (XYPLOT 2010) and then entered data
into the ReviewManager software to be analysed (RevMan 2014).
Assessment of risk of bias in included studies
While interrogating each study report for the extraction of data,
the authors also noted information regarding the conduct and de-
sign of each study in order to implement the Cochrane Collabo-
ration’s risk of bias tool (Higgins 2011b). This tool facilitates the
assessment of biases introduced through inadequacies in random
sequence generation, allocation concealment, blinding of partici-
pants and study personnel, blinding of outcome assessments, re-
porting of incomplete outcome data and selective reporting. As
with data extraction, the two investigators extracted this informa-
tion with the same process for comparison and resolution of dis-
parity. Theywere not blinded to the authors of each study. In some
instances more information is required and in future the review
authors will attempt to contact the study authors or sponsors for
more detail to be included in updates of this review. All investiga-
tors agreed the final judgement regarding whether any individual
bias or group of biases imposes a material bias impacting upon
the results and conclusions of a study, informed by the empirical
evidence, likely direction and magnitude of any bias.
Measures of treatment effect
The authors assessed continuous outcomes (lung function, nutri-
tional status, quality of life and symptom scores) by the calcula-
tion of mean difference (MD) and 95% confidence intervals (CIs).
Where trials reported multiple measures for the same outcome
(e.g. absolute change FEV1 per cent (%) predicted, or absolute
change of absolute FEV1 volumes) the review authors calculated
standardised mean differences (SMDs). In the event that individ-
ual participant data had been available, the authors would have
considered absolute changes in FEV1 in context of comparable
data being available for each participant before and after the in-
tervention so that a calculation of the effect size was possible.
If the data allowed, the authors would have extracted or calculated
hazard ratios (HR) and 95% CIs for the outcome ’Time to next
exacerbation’. Where possible, the authors evaluated dichotomous
outcome data for death by the calculation of a risk ratio (RR) with
95% CIs. If it had been possible, they planned to assess adherence
by calculating odds ratio (OR) with 95%CIs. Other dichotomous
outcomes would have been reported by the calculation of ORs
with 95% CIs.
Unit of analysis issues
The authors aimed to only consider the first pulmonary exacerba-
tion for each participant, taking the measure of effect as the dif-
ference between baseline and the end of treatment. The optimal
duration of therapy is yet to be established and so the authors con-
sidered the end of therapy measurement (as defined in the study)
as the unit of analysis. In the case of cross-over studies they aimed
to consider only the first phase of participation, as participants
may not recover lung function to baseline (Sanders 2010) and,
in addition to introducing a unit of analysis error, multiple treat-
ment episodes may not be comparable. In effect, these studies re-
main listed in Studies awaiting classification as the authors await
data to include in the analysis. In order to compare interventions
of differing durations the authors aimed, given sufficient compa-
rable studies reporting these data, to combine outcome data for
comparisons at two weeks, three months and one year after the
exacerbation. If future studies consistently report this, they shall
undertake this analysis in future updates.
Dealing with missing data
When possible the review authors aimed to contact the study au-
thors for data that appeared to be missing. Where only mean val-
ues and standard deviations (SDs) before and after treatment were
available, they imputed the SD of the mean change using a cor-
relation coefficient as described in theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011a). For the calcu-
lation of a correlation coefficient for studies that reported FEV1
and FVC in terms of % predicted, the authors used data from the
1988 Bosso study, as this study reported the mean and SD for pre-
treatment and post-treatment and also the SD of the mean change
(Bosso 1988). Similarly, for studies that reported FEV1 and FVC
in absolute change (litres) the authors used data from the 1987
Hodson study (Hodson 1987). When appropriate to do so, the
authors may remedy missing data by the imputation of replace-
ment values (e.g. using the mean value for a treatment group).
Where possible they will conduct intention-to-treat analyses.
Assessment of heterogeneity
Where the review authors were able to perform a meta-analysis
with multiple studies suitable for inclusion, they attempted to
identify statistical heterogeneity by calculating a Chi2 test and us-
ing this value to compute an I2 statistic (Higgins 2003). They inter-
preted this value based on thresholds as identified in theCochrane
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Handbook for Systematic Reviews of Interventions (Deeks 2011): 0%
to 40% as probably not important; 30% to 60% as moderate het-
erogeneity; 50% to 90% as substantial heterogeneity; and 75% to
100% as considerable heterogeneity. The authors also considered
sources of heterogeneity within the characteristics of the included
studies.
Assessment of reporting biases
The review authors used multiple search methods to identify pub-
lished studies and also aimed to contact the authors of all included
studies in an attempt to identify studies that may not have been
published. They also aimed to contact the authors of any study
published only in abstract form for study data. Where available,
they attempted to identify evidence of outcome reporting biases
by the comparison of the published report to the study protocol.
They further attempted to identify reporting biases by the con-
struction and inspection of funnel plots for asymmetry and in-
terpreting them in the context of study sizes, and methodological
rigour (Sterne 2011).
Data synthesis
The authors conducted separate meta-analyses for the grouped
comparisons as detailed above (Types of interventions). They con-
ducted a fixed-effect method meta-analysis to combine the mea-
sures of effect for the outcomes of study. In the case of at least
substantial heterogeneity (as defined above), they would have em-
ployed a random-effects method.
The authors used the inverse variance method of meta-analysis for
continuous data and the Mantel-Haenzsel method for dichoto-
mous data as the default fixed-effect methods in RevMan. The
authors would have used the generic inverse variance method for
the outcome ’time to next pulmonary exacerbation’ if data had
been available for analysis.
Subgroup analysis and investigation of heterogeneity
In the case that the authors had identified a sufficient number of
studies (i.e. 10), they would have undertaken subgroup analyses
for the following groups:
• bacteria isolated at time of exacerbation P. aeruginosa versus
non P. aeruginosa;
• severity of lung disease based on a composite of age and
FEV1 to delineate ’severe’ and ’mild’ as classified by Schluchter
(Schluchter 2006); and
• age of participants (children (less than 18 years of age) and
adults).
Sensitivity analysis
Again, if the authors had identified a sufficient number of stud-
ies for inclusion, they would have investigated the effect of arbi-
trary decisions made by the review team by undertaking sensitivity
analyses of the affected components. In the case where they de-
cided to manage missing data by the imputation of data, if possi-
ble they would have investigated the effect of these manipulations
by repeating the analyses without these imputations. In the case
of determining the effect of arbitrary decisions the authors made,
for example by including all studies of pulmonary exacerbations
instead of limiting selection only to those with stricter diagnos-
tic criteria, they would have repeated the analyses limited to the
stricter diagnostic criteria.
Summary of findings tables
In a post hoc change the authors have presented three summary of
findings tables - one comparing single and combination IV antibi-
otics, one comparing nebulised and IV antibiotics and one com-
paring oral and IV antibiotics (Summary of findings for the main
comparison; Summary of findings 3; Summary of findings 2). The
authors calculated the assumed risk as themean of the effect size of
the control group in each study; the corresponding risk being the
result of the meta-analysis as presented in the data tables. The au-
thors determined the study quality using the GRADE approach,
where quality was rated with regard to risk of bias or study lim-
itations, directness, consistency of results, precision, publication
bias and effect size. They downgraded the evidence by one level
for serious (or by two for very serious) study limitations.
R E S U L T S
Description of studies
For study details please refer to the tables (Characteristics
of included studies; Characteristics of excluded studies;
Characteristics of studies awaiting classification).
Results of the search
The original search (November 2011) identified 180 publications
and a later search (July 2014) identified a further 12. The search
of the Cystic Fibrosis and Genetic Disorders Group’s Trials Reg-
ister in 2015 did not identify any new publications. A search of
the reference lists of these publications (and reviewing other pub-
lications included within the same supplementary journal issues)
identified a further 17 published reports. Of these 209 published
reports, of which some were duplicate reports of the same study,
we identified 134 individual studies. We were able to exclude 82
studies after reviewing the abstracts or full reports (132 references)
for the reasons stated below (Excluded studies). There were 40
trials (62 references) that met our inclusion criteria; 12 studies (15
references) await classification (see PRISMA diagram Figure 1).
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Figure 1. Study flow diagram.
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Included studies
A total of 40 studies (n = 1717) were included in the review (
Characteristics of included studies). Many of the included studies
are older, with only three studies reporting since 2000 (Blumer
2005; Master 2001; Semykin 2010).
Trial design
A total of 14 studies were described as double-blind and a further
seven studieswere single-blind (an additional four involved a single
assessment modality that was blinded); the remaining 18 studies
were unblinded. All studies were of a parallel design; cross-over
studies are awaiting pending data for inclusion (see Characteristics
of studies awaiting classification).
Most of the studies were single-centre studies; however, one study
had two centres (McLaughlin 1983) and a further five studies were
multi-centre (three or more centres) (Blumer 2005; BTS 1985;
Church1997;Richard 1997; Smith 1999). Themajority of studies
were conducted either in Western Europe (n = 17) or the USA (n
= 15) with the remaining studies taking place in Canada (n = 4),
Australia (n = 2), New Zealand (n = 1), Russia (n = 1) and one
study was multinational (Richard 1997).
A total of 33 studies compared two groups of participants, five
studies compared three groups (Costantini 1982; McLaughlin
1983; Padoan 1987; Semykin 2010; Wang 1988) and a further
two studies had four arms (Macfarlane 1985) and seven arms (
Agostini 1983). The duration of the interventions ranged from
three days (Caplan 1984) to 15 days (Agostini 1983; Costantini
1982; Schaad 1987), although the vastmajority of studies reported
an administration of antibiotics of 14 days.
Participants
The included studies involved a total of 1717 participants. How-
ever, many of these studies each recruited only a small number
of participants; indeed, 28 studies recruited fewer than 50 partic-
ipants. The largest study randomised 147 participants (Agostini
1983), while the smallest recruited just 13 participants (Wesley
1988).
Five studies included only children (which we defined as younger
than 18 years) (Church 1997; Knowles 1988; Padoan 1987;
Semykin2010;Wesley1988) and four studies recruited only adults
(Bosso 1989; Hodson 1987; Penketh 1984; Wang 1988). The re-
maining studies admitted participants of all ages. Where data were
available regarding gender split, groups were largely equally split,
except for five studies where males were predominant (Gold 1985;
Penketh 1984; Regelmann 1990; Salh 1992; Stephens 1983) and
three studies where females were predominant (Gold 1987;Huang
1983; Padoan 1987).
Few studies described the disease severity of the participants; those
that did largely did so on the basis of FEV1 (Blumer 2005; Church
1997; Conway 1997), while two explicitly enrolled those with “se-
vere” disease (Padoan 1987; Wesley 1988). Other studies actively
excluded those with severe disease; two studies excluded those with
protocol-defined severe disease (Gold 1985; Schaad 1986), while
a further two studies did so on the basis of lung function - one
excluded those with FEV1 less than 40% predicted (Master 2001)
and the second excluded those with FEV1 less than 20% predicted
(Penketh 1984). One study excluded those who had been admit-
ted to hospital more recently than four months prior to the current
admission (Schaad 1989).
Interventions
IV antibiotic versus placebo
We identified seven studies that investigated the activity of an IV
antibiotic regimen with a placebo in the comparison (Gold 1987;
Hyatt 1981; Macfarlane 1985; McLaughlin 1983; Regelmann
1990; Smith 1999; Wientzen 1980). While three of these were
direct comparisons of an intervention versus placebo (Gold 1987;
Regelmann 1990; Wientzen 1980), four trials involved a placebo
drug as part of an IV antibiotic combination, thereby attempting
to consider the effect of single active agent versus combination
agent treatment and are further discussed in the section below
(Single IV antibiotic versus combination IV antibiotic) (Hyatt 1981;
Macfarlane 1985; McLaughlin 1983; Smith 1999).
Single IV antibiotic versus placebo
Two studies involved a direct comparison between a single antibi-
otic (ceftazidime and tobramycin respectively) and placebo (Gold
1987; Wientzen 1980).
Combination of IV antibiotics versus placebo
One further study compared an antibiotic combination (to-
bramycin and ticarcillin) and placebo (Regelmann 1990) .
IV antibiotic regimens compared
A total of 29 studies compared multiple IV antibiotic regimens.
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Single IV antibiotic regimens compared
Six studies compared two (or more) different single antibiotic
regimens (Agostini 1983; Caplan 1984; Costantini 1982; Elborn
1992;Huang 1983; Salh 1992).One study comparedfive different
antibiotics - azlocillin versus piperacillin versus ceftazidime versus
cefsulodin versus cefoperazone (Agostini 1983); a further study
compared cefsulodin to tobramycin or ticarcillin (Caplan 1984).
The remaining three studies compared two single IV antibiotics:
ceftazidime versus aztreonam (Elborn 1992); carbenicillin versus
azlocillin (Huang 1983); and ceftazidime versus aztreonam (Salh
1992). Two arms of the Costantini trial compared carbenicillin
alone to sisomycin alone (Costantini 1982).
Single IV antibiotic versus combination IV antibiotic
Four studies involved a placebo drug as part of an IV antibiotic
combination, thereby attempting to consider the effect of sin-
gle active agent versus combination agent treatment (Hyatt 1981;
Macfarlane 1985; McLaughlin 1983; Smith 1999). Hyatt studied
oxacillin in combination with placebo compared to a combina-
tion of oxacillin, sisomycin and carbenicillin (Hyatt 1981). Mac-
Farlane considered two doses of piperacillin (50 mg/kg six times
daily and 100 mg/kg three times daily) each in combination with
tobramycin compared to tobramycin with placebo (Macfarlane
1985). McLaughlin compared the combination of ticarcillin and
tobramycin to a combination of azlocillin and tobramycin and
further compared these with azlocillin and placebo (McLaughlin
1983). In the final study, Smith considered the combination of
azlocillin and tobramycin compared with azlocillin and placebo
(Smith 1999).
A total of 12 separate studies compared a single IV antibiotic with
a combination of two IV antibiotics; of these five investigated the
use of combination antibiotic treatment by comparing the effect
of a single antibiotic with the same antibiotic in combination
with another agent (Conway 1997;Costantini 1982;Master 2001;
McCarty 1988; Padoan 1987) and seven compared a single agent
to two different antibiotics in combination (Bosso 1988; BTS
1985; De Boeck 1989; De Boeck 1999; Gold 1985; Padoan 1987;
Wesley 1988). One study consisted of multiple comparison arms
which fall into both these comparisons (Padoan 1987). Another,
compared a combination of IV antibiotics with a different IV
antibiotic followed by the same antibiotic in oral form (Church
1997).
The antibiotics and their combinations used were varied, none of
the studies comparing a single IV antibiotic to combination IV an-
tibiotics used the same single agent. One study compared colistin
alone to a combinationof colistinwith either aztreonam, azlocillin,
piperacillin, ceftazidime, imipinem, or ciprofloxacin (Conway
1997). A second study compared tobramycin to tobramycin with
ceftazidime (Master 2001). A further study compared piperacillin
to piperacillin with tobramycin (McCarty 1988). In addition to
the two single-agent comparison arms of the Costantini trial men-
tioned above (carbenicillin alone to sisomycin alone), the trial also
compared each single agent alone to carbenicillin combined with
sisomycin (Costantini 1982). A further trial with multiple com-
parison arms compared ceftazidime alone to ceftazidime with si-
somycin (Padoan 1987). The seven studies comparing a single
agent with a combination of two different antibiotics also used a
range of different agents. Ceftazidime was used as the single agent
in five studies, it was compared to: gentamicin plus carbenicillin
(BTS 1985); tobramycin plus piperacillin (De Boeck 1989); to-
bramycin plus ticarcillin (Gold 1985; Wesley 1988) and, in ad-
dition to the comparison discussed above, to piperacillin plus si-
somycin (Padoan 1987). Ceftazidime was also used in combina-
tion with tobramycin and compared to meropenem alone in one
study (De Boeck 1999). The final study compared aztreonam to
tobramycin plus azlocillin (Bosso 1988).
Combination IV antibiotic regimens compared
Nine studies compared two combinations of two different IV
antibiotics (Blumer 2005; Conway 1985; McLaughlin 1983;
Penketh 1983; Penketh 1984; Schaad 1986; Schaad 1989;
Semykin 2010; Wang 1988). Again the IV antibiotics used were
varied. Two studies administered a combination of netilmicin
and ticarcillin, but compared these to tobramycin and ticarcillin
(Conway 1985) and netilmicin and azlocillin (Schaad 1986). Two
studies by the same lead author compared carbenicillin and gen-
tamicin to other IV antibiotic combinations, firstly, carbenicillin
plus gentamicin versus ticarcillin plus gentamicin (Penketh 1983)
and secondly carbenicillin plus gentamicin versus azlocillin plus
gentamicin (Penketh 1984). The remaining two studies compared
meropenem plus tobramycin versus ceftazidime plus tobramycin
(Blumer 2005) and aztreonam plus amikacin versus ceftazidime
plus amikacin (Schaad 1989). Semykin compared IV cefepime
plus IV amikacin to IV meropenem plus IV amikacin, in addition
to a nebulised antibiotic arm (discussed below) (Semykin 2010).
McLaughlin considered the combination of ticarcillin plus to-
bramycin compared with azlocillin plus tobramycin (as well as an-
other arm with a placebo as discussed above) (McLaughlin 1983).
IV antibiotic regimen versus nebulised antibiotics
A total of five studies compared IV antibiotics to nebulised antibi-
otics.
One study compared an IV antibiotic regimen with an inhaled an-
tibiotic regimen using IV tobramycin and ticarcillin compared to
inhaled tobramycin and inhaled carbenicillin (Cooper 1985). Four
studies investigated the effect of inhaled antibiotics as an adjunct to
intravenous antibiotic use (Knowles 1988; Schaad 1987; Semykin
2010; Stephens 1983). Knowles compared IV piperacillin and IV
tobramycin to IVpiperacillin and IV tobramycinwith the addition
of these same antibiotics delivered by nebuliser (Knowles 1988).
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Similarly, Stephens compared IV ticarcillin and IV tobramycin to
IV ticarcillin and IV tobramycin with the addition of inhaled to-
bramycin (Stephens 1983) and Schaad compared IV ceftazidime
and IV amikacin to IV ceftazidime and IV amikacin with the ad-
dition of inhaled amikacin (Schaad 1987). The fourth study to
compare IV antibiotics to nebulised antibiotics compared IV ce-
fepime with IV amikacin to IV meropenem and IV amikacin and
also to inhaled tobramycin given alongside IV ceftazidime and oral
ciprofloxacin (Semykin 2010).
IV antibiotic regimen versus oral antibiotics
Six studies compared IV antibiotics to oral antibiotics.
Four studies compared oral ciprofloxacin with two-agent IV com-
binations (Bosso 1989;Hodson 1987;Richard 1997;Wang 1988).
One study compared oral ciprofloxacin to IV azlocillin with gen-
tamicin (Hodson 1987) and another study compared it to IV cef-
tazidime with tobramycin (Richard 1997). A further study com-
pared oral ciprofloxacin to IV tobramycin with azlocillin (Bosso
1989) and the remaining study had a three-arm comparison of
oral ciprofloxacin to IV tobramycin with azlocillin and to IV to-
bramycin and ticarcillin (Wang 1988).
A fifth study compared oral ciprofloxacin with oral ciprofloxacin
cycledwith IV tobramycinwith azlocillin (Black 1990).One study
compared IV ciprofloxacin followed by oral ciprofloxacin to IV
tobramycin with IV ceftazidime (Church 1997).
Multiple comparisons
Among the studies described above, six included multiple com-
parisons within a single study (Church 1997; Costantini 1982;
McLaughlin 1983; Padoan 1987; Semykin 2010; Wang 1988).
Church compared single agent IV ciprofloxacin followed by sin-
gle agent oral ciprofloxacin with combination treatment with IV
tobramycin and IV ceftazidime with multiple reporting periods
thus comparing both single with combination IV agents and oral
compared with IV (Church 1997). Costantini compared IV car-
benicillin to IV sisomycin each as single agents and to IV carbeni-
cillin with sisomycin combined (Costantini 1982). McLaughlin
compared IV ticarcillin with IV azlocillin each in combination
with IV tobramycin and also with a third comparison group of IV
azlocillin in combination with placebo (McLaughlin 1983).
Padoan compared IV ceftazidime to IV ceftazidimewith sisomycin
and to IV piperacillin with sisomycin (Padoan 1987). Semykin
compared IV cefepime with IV amikacin to IV meropenem and
IV amikacin and to inhaled tobramycin given alongside IV cef-
tazidime and oral ciprofloxacin (Semykin 2010). Wang studied
oral ciprofloxacin compared to IV tobramycin with ticarcillin and
to IV tobramycin with azlocillin (Wang 1988).
Outcomes
Some of the earlier studies reported clinical status in the form of a
’clinical score’. These were not standardised or validated and the
components of the scores varied between studies. Many studies
did not report absolute values of measures, instead detailing the
results of a statistical comparison between groups.
Lung function was the most commonly reported outcome (32
studies); however, this was variably reported as either percentage
change or absolute change in either % predicted or absolute val-
ues of FEV1 or FVC. This made comparing the results of similar
studies difficult. In addition, few studies reported means and mea-
sures of distribution of all lung function measurements - initial,
end measurements and a measure of the change over time. Where
necessary we imputed the SDs for change using a correlation co-
efficient that was calculated from those studies that did report the
requisite information, namely for data reported as FEV1 % pre-
dicted, a correlation coefficient was calculated using data from the
Bosso study (Bosso 1989) and for data reported as absolute values,
a correlation coefficient was calculated using data in the Hodson
study (Hodson 1987).
Studies infrequently reportednutritional status and again variously
- either in absolute terms or as ameasure of% underweight. Time-
to-next exacerbation was reported in only eight studies; and then
with data suitable for use in ameta-analysis only available from two
studies (De Boeck 1989; McLaughlin 1983). Two studies report
rates of re-admission in the threemonths following the study (BTS
1985; Wesley 1988). Three studies report a statistical test without
supporting data (Penketh 1983; Penketh 1984; Smith 1999).
Adverse effects were variably reported in 26 studies, consisting of
either specific reports of toxicities (ototoxicity or nephrotoxicity)
(Penketh 1983; Regelmann 1990; Schaad 1987; Schaad 1989),
screens for general toxicities using serummarkers of liver and renal
function or reports of side effects (Agostini 1983; Black 1990;
Bosso 1988; BTS 1985; Caplan 1984; Conway 1997; Costantini
1982; Huang 1983; Hyatt 1981; Macfarlane 1985; Master 2001;
Padoan 1987; Penketh 1983; Schaad 1986; Schaad 1987; Wang
1988; Wesley 1988), or discussion of bacterial resistance patterns
(Church 1997; Gold 1985; Hodson 1987; McLaughlin 1983;
Penketh 1984; Salh 1992; Stephens 1983).Mortality was reported
in seven studies (Caplan 1984; Conway 1985; De Boeck 1989;
Hyatt 1981; McLaughlin 1983; Penketh 1984; Wientzen 1980).
Quality of life and adherence were not reported in any study.
Excluded studies
A total of 82 studies were excluded (Characteristics of excluded
studies). Fifteen studies were not randomised (or were quasi-ran-
domised) (Cabezudo 1984; Hoogkamp-Korstanje 1983; Jackson
1986; Jewett 1985; Krause 1979; Kuni 1992; Levy 1982a; Martin
1980; Michalsen 1981; Parry 1977; Popa 2001; Postnikov 2001;
Postnikov 2001a; Rubio 1987; Shatunov 2001). Six studies related
to treatment location, e.g. at home versus in hospital (Amelina
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2000; Davis 1990; Donati 1987; Hjelte 1988; Klettke 1999;
Wolter 1997). Seven studies were excluded since they did not in-
clude participants being treated for pulmonary exacerbations in
both comparison arms (Brett 1992; Byrne 1995; Elborn 2000;
Jensen 1987; Pedersen 1986; Permin 1983; Yasmin 1974). Five
studies did not include an IV antibiotic comparator (Day 1988;
Gold 1983; Heaf 1984; Levy 1982; Nikonova 2010). Two were
excluded as the comparison was one of process; bronchoscopy-
guided management (Wainwright 2011) or pharmacist versus
self-care (Ramstrom 2000). Three studies were observational or
non-intervention studies (Dodge 1983; Hatziagorou 2013; Moss
1991) and two studies were in vitro studies (Aaron 2005; Balsamo
1986). The remaining 42 studies relate to dosing studies or
pharmacokinetic or pharmacodynamic studies or toxicity stud-
ies (Adeboyeku 2011; Al-Ansari 2006; Aminimanizani 2002;
Beringer 2003; Beringer 2010; Burkhardt 2006; Canis 1998;
Christensson 1992; Conway 1996a; Davis 1987; De Boeck 1998;
Degg 1996; Eron1983;Goldfarb1987;Guglielmo1996;Hamner
2006; Heininger 1993; Hubert 2009; Ivanov 1997; Jacobs 1985;
Keel 2011; Kercsmar 1983; Kruger 2001; Kuzemko 1989; Labiris
2004; Li 1991; McCabe 2013; Mouton 1991; Nikolaizik 2005;
Padoan 1988; Postnikov 2007; Powell 1983; Prayle 2013; Reed
1987; Reed 1987a; Riethmueller 2009; Roberts 1992; Smyth
2005; Turner 2013;Whitehead 2002;Winnie 1991;Wood 1996).
Studies awaiting classification
For 12 studies (15 references) we were unable to make a deci-
sion regarding inclusion or exclusion. For four of the studies it
was unclear if the study was randomised (Crawley 2005; Huang
1979; Kapranov 1995; Vic 1997).We are awaiting data that report
includable participant episodes in the case of the four cross-over
studies (Al-Aloul 2005; Dinwiddie 1982; Döring 1995; Geborek
2003), one of which included a placebo arm (Döring 1995), and
also the two studies that report multiple indications (e.g. exac-
erbations and suppressive regimens) (Latzin 2008; Parry 1978).
The Beaudry study met our eligibility criteria, but did not report
any outcomes listed in this review (Beaudry 1980). Finally, one
abstract was cited in the reference list of a further article, we have
not been able to access this abstract yet and as such details about
participants, methods and interventions are still unclear (Harris
1984). In these cases we shall contact the study investigators for
clarification or additional data and will make a decision regarding
inclusion or exclusion based upon the responses received.
Risk of bias in included studies
The assessment of risk of bias in the included studies is summarised
in the figures (Figure 2; Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
All studies were described as being randomised, although few de-
scribed the method of generating the allocation sequence. Hence
most included studies have been classified as being at an unclear
risk of bias for this domain. In two studies, while it was stated that
randomisation was carried out by pharmacists, the details of the
method were not described and so the authors considered the risk
of bias to be unclear (McLaughlin 1983; Salh 1992). A further
study stratified randomisation by disease severity and age; how-
ever, again the method of randomisation used was not stated and
so this study was also considered to be at an unclear risk of bias
(Master 2001). Six studies were judged to be at a low risk of bias for
sequence generation; four studies used a table of random numbers
(Gold 1985; Hyatt 1981; Regelmann 1990; Wientzen 1980) and
a further two were randomised by a randomisation code (Huang
1983; Smith 1999).
Allocation concealment
Four studies described either sequentially numbered envelopes or
opaque envelopes as a mechanism for concealing allocation af-
ter randomisation (BTS 1985;McCarty 1988;McLaughlin 1983;
Salh 1992). While no study used both sequential numbering or
made clear that the envelopes were opaque, the authors regarded
these studies to be at a low risk of bias with regard to allocation con-
cealment. One study stated that both the antibiotics and placebo
were prepared in the pharmacy and delivered in coded bottles; the
code was not broken in case of ’treatment failure’ (Hyatt 1981).
This study was also considered to have a low risk of bias from
allocation concealment. All other studies were considered to be at
an unclear risk of bias due to insufficient information.
Blinding
Fourteen studies were described as double blind. Six of these stud-
ies involved the preparation of identical syringes or infusions pre-
pared in pharmacy with adequate blinding of outcome assessment
and so we felt them to be at a low risk of bias (Hyatt 1981;
Macfarlane 1985;Master 2001; Salh 1992; Smith 1999;Wientzen
1980).
We judged the remaining eight studies which were described as
double-blind to have an unclear risk of bias. The Gold study at-
tempted to blind both participants and outcome assessors; how-
ever, participant blinding was potentially compromised by partic-
ipants being able to detect a characteristic odour from urine when
they were treated with ceftazidime (Gold 1987). The effect of this
has been classified as ’unclear’ as it is unknown what proportion of
participants had previously received ceftazidime and noticed the
characteristic change (or otherwise); although it is noted that three
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participants who withdrew had correctly guessed that they were
receiving placebo due to absence of urine odour. The Regelmann
study involved the generation of sham drug levels, although no
further detail was given and so we considered the study to also be
at an unclear risk of bias (Regelmann 1990). The remaining six
trials did not describe the method of participant blinding and so
the risk of bias is also considered to be unclear (Agostini 1983;
Church 1997; Huang 1983; McLaughlin 1983; Padoan 1987;
Wesley 1988).
Eight studies were considered to be at a high risk of both per-
formance and detection bias due to an open study design (Bosso
1988; Bosso 1989; BTS 1985; Conway 1985; McCarty 1988;
Penketh 1983; Penketh 1984; Richard 1997).
Performance bias
Seven studies were considered to be at a low risk of performance
bias due to adequate evidence of blinding of participants (Hyatt
1981; Macfarlane 1985; Master 2001; McLaughlin 1983; Salh
1992; Smith 1999;Wientzen 1980); 13 studies were considered to
be at a high risk of performance bias due to no blinding of partici-
pants (Bosso 1988; Bosso 1989; BTS 1985; Caplan 1984; Conway
1985; Conway 1997; De Boeck 1989; Gold 1985; Knowles 1988;
McCarty 1988; Penketh 1983; Penketh 1984; Richard 1997).
With the remaining 20 studies we were unable to make an assess-
ment due to insufficient information.
Detection bias
Thirteen studies were considered to be at a low risk of detection
bias due to adequate evidence of outcome assessor blinding (De
Boeck 1989; Gold 1985; Gold 1987; Hyatt 1981; Macfarlane
1985; Master 2001; McLaughlin 1983; Salh 1992; Schaad 1987;
Schaad 1989; Smith 1999; Stephens 1983;Wientzen 1980). Eight
studies were considered to be at a high risk of detection bias due
to an open study design (Bosso 1988; Bosso 1989; BTS 1985;
Conway 1985; McCarty 1988; Penketh 1983; Penketh 1984;
Richard 1997). With the remaining 19 studies we were unable to
make an assessment due to insufficient information.
Incomplete outcome data
Twelve studies were considered to be at a low risk of attrition bias;
eight studies documented that there were no participants who
withdrew during the study period and as such are considered to be
at a low risk of bias (Bosso 1988; Caplan 1984; De Boeck 1989;
Gold 1985; Hodson 1987; McCarty 1988; Penketh 1984; Schaad
1987). A further four studies reported an intention-to-treat anal-
ysis, or reported the last contributed data for those who withdrew
and so are also considered to be at a low risk of bias (Conway
1997; Hyatt 1981; Master 2001; Richard 1997). Fourteen stud-
ies did not include participants who withdrew in the analysis (or
where incomplete data are presented) and are considered to be
at a high risk of bias (Agostini 1983; Blumer 2005; Bosso 1989;
BTS 1985; Church 1997; Gold 1987; Huang 1983; Macfarlane
1985; McLaughlin 1983; Regelmann 1990; Schaad 1986; Schaad
1989; Smith 1999; Wientzen 1980). In some analyses this effect
reaches a considerable proportion of the overall study group, as
exemplified by the four studies contributing to the analysis of sin-
gle IV antibiotics in combination with placebo versus combina-
tion IV antibiotics where 23% of participants do not contribute
to the final analysis. Also in the comparison of a single agent (no
placebo) versus an antibiotic combination, there were 10 studies
(345 participants) reporting on FEV1; however only four studies
with 152 participants contribute to the analysis.
Additionally, in the Wientzen study two participants died in the
placebo group (one on Day 1 and the second on Day 4). Due
to the small study size this is surprising and so suggests either a
failure of random allocation or a difference in the characteristics
of the comparator groups at baseline (Wientzen 1980). In the
Regelmann study, one participant was withdrawn by the attending
physician for “failing to improve rapidly enough”. Furthermore of
the 15 participants, only four in the placebo group and eight in
the antibiotic group contribute data to the final analysis at two
weeks (Regelmann 1990). Both studies are therefore considered
to be at high risk of bias in the domain of incomplete outcome
data.
The remaining 15 studies did not report details concerning with-
drawals or adequacy of reporting to allow an assessment to be
made.
Selective reporting
The inadequate reporting of studies made it difficult to reach a
decision regarding selective reporting in the majority of instances.
This was largely due to many of the included studies being un-
dertaken prior to the establishment of trial registries and routine
archiving of study protocols. In two studies it was clear that lung
function data had been recorded but not reported (Black 1990;
Caplan 1984) and another stated that time-to-next exacerbation
data were recorded, but not reported (Knowles 1988). We consid-
ered these studies to have a high risk of bias. We were unable to
retrieve the protocols for any study and so were unable to deter-
mine a study to be at a low risk of bias.
Other potential sources of bias
An additional issue with the outcomes addressed in this review
is the heterogeneity with which they are reported, not only in
terms of the wide variety of units for change in lung function
(absolute change, percentage change in absolute values (litres),
per cent change in % predicted values) but also the variety of
measures reported (BMI, weight, proportion underweight) that
make contributing studies to a meta-analysis challenging.
A unit of analysis issue was introduced in 20 studies which
involved people who participated on more than one occasion
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in a study (Agostini 1983; BTS 1985; Conway 1985; Conway
1997; Costantini 1982; De Boeck 1999; Gold 1987; Hyatt 1981;
Macfarlane 1985; Master 2001; McCarty 1988; Padoan 1987;
Regelmann 1990; Salh 1992; Schaad 1986; Schaad 1987; Schaad
1989; Wang 1988; Wesley 1988; Wientzen 1980). In some cir-
cumstances the proportion of re-admittances to the study was con-
siderable. In the Conway study, 18 out of 53 participants con-
tributed multiple data points (34%). This was not only a con-
siderable proportion within the study, but this also contributed a
substantial degree of weight (47.1%) contributed to the analysis
(Analysis 5.4).
In addition in the Penketh study, participants who isolated other
(non-pseudomonas) bacteria at baseline received “appropriate oral
antibiotics” although the antibiotics, and distribution of adminis-
tration are not noted (Penketh 1984).
We could identify no other sources of bias except in one study
where a co-author was affiliated to a pharmaceutical company that
produced a drug in test (Richard 1997) and another study that was
funded by a pharmaceutical company that produced a drug under
test (Smith 1999). In neither case did we have enough information
to reach a decision on the effect these relationships had toward
bias.
Effects of interventions
See:Summaryoffindings for themain comparison Single versus
combination IV antibiotics for pulmonary exacerbations in people
with cystic fibrosis; Summary of findings 2Nebulised antibiotics
compared to IV antibiotics for pulmonary exacerbations in people
with cystic fibrosis; Summary of findings 3 Oral antibiotics
compared to IV antibiotics for pulmonary exacerbations in people
with cystic fibrosis
Due to the large number of comparisons and outcomes measures,
we have only reported below on those for which we either have
data or narrative information.
IV antibiotic versus placebo
Single IV antibiotic versus placebo
Two studies with 48 participants compared a single IV antibiotic
to placebo (Gold 1987; Wientzen 1980). Gold administered cef-
tazidime to 26 individuals (31 events) at a dose of 200 mg/kg/day
(Gold 1987). Wientzen administered tobramycin to 22 individu-
als (24 events) at a dose of 2 mg/kg three times daily (Wientzen
1980). Both studies involve inherent attrition biases and unit of
analysis issues (Figure 3).
Primary outcomes
1. Lung function
Gold reported both FEV1 and FVC data (see below) (Gold 1987).
Wientzen reported the number of participants who demonstrated
improved pulmonary function, whichwas defined as a greater than
15% improvement in two of FEV1, FVC or PEFR; four out of
six participants in the tobramycin group improved, but none of
the seven participants in the placebo group met this improvement
criterion (Wientzen 1980). The study investigators found this dif-
ference significant (P < 0.05).
a. FEV1
Gold reported data for the percentage (relative) change in FEV1 %
predicted; however, these are reported as means and 95% CIs with
a typographical error in the CI for the placebo group, making the
use of these data impossible. The study authors, however, conclude
that “no significant differences were seen in any outcomemeasure”
(Gold 1987).
b. FVC
Gold also reported the percentage (relative) change in % predicted
FVC (Gold 1987). Values for SDs were calculated from the stated
CIs; however, two of the participants had two episodes where they
received ceftazidime and therefore contribute data to the interven-
tion group twice. There was no difference detected between the
two groups when data were analysed, MD 13.00% (95% CI -1.23
to 27.23) (Analysis 1.1).
Secondary outcomes
2. Nutritional status
b. Weight
Gold reported mean weight gain as a percentage of initial weight
(Gold 1987). Again, two of the participants had two episodes
where they received ceftazidime and therefore contribute data to
the intervention group twice.There was no difference between the
two groups, MD 0.50% (95% CI -1.78 to 2.78) (Analysis 1.2).
4. Mortality
In theWientzen study, two participants in the placebo group died;
one after 24 hours of treatment with placebo, the second partici-
pant received two days of placebo treatment then changed to an-
tibiotic treatment and died two days later (Wientzen 1980). Gold
reported no deaths (Gold 1987).
5. Adverse effects
a. toxicity and allergy
Wientzen only reported on nephrotoxicity, but did not detect this
in either group (Wientzen 1980).
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Combination of IV antibiotics versus placebo
One study with 15 participants compared a combination of IV
antibiotics (tobramycin and ticarcillin) to placebo (Regelmann
1990).Datawere presented graphically and so these were extracted
using XYPLOT (XYPLOT 2010). By the end of the study only
eight participants in the antibiotic group and four in the placebo
group contributed data.
Primary outcomes
1. Lung function
a. FEV1
Data reported for absolute change in % predicted FEV1 demon-
strated a statistically significant improvement in favour of IV an-
tibiotics, MD 16.80% (95% CI 13.17 to 20.43) (Analysis 2.1).
b. FVC
Data reported for absolute change in % predicted FVC also
demonstrated a statistically significant improvement in favour of
IV antibiotics, MD 15.40% (95% CI 11.96 to 18.84) (Analysis
2.2).
Secondary outcomes
2. Nutritional status
Both groups reported increased weight with no difference between
groups (no data presented).
5. Adverse effects
a. toxicity and allergy
No ototoxicity or blood parameter changes were noted in either
group.
IV antibiotic regimens compared
A total of 29 studies with 1446 participants (reporting data from
1035 participants) compared one regimen of IV antibiotics to an-
other IV regimen (either with or without placebo) (Agostini 1983;
Blumer 2005; Bosso 1988; BTS 1985; Caplan 1984; Church
1997; Conway 1985; Conway 1997; Costantini 1982; De Boeck
1989; De Boeck 1999; Elborn 1992; Gold 1985; Huang 1983;
Hyatt 1981; Macfarlane 1985; Master 2001; McCarty 1988;
McLaughlin 1983; Padoan 1987; Penketh 1983; Penketh 1984;
Salh 1992; Schaad 1986; Schaad 1989; Semykin 2010; Smith
1999; Wang 1988; Wesley 1988).
Single IV antibiotic regimens compared
Five studies with 251 participants compared two (or more) single
antibiotic regimens (Agostini 1983; Caplan 1984; Elborn 1992;
Huang 1983; Salh 1992). Agostini (n = 147) compared five dif-
ferent antibiotics - azlocillin versus piperacillin versus ceftazidime
versus cefsulodin versus cefoperazone (Agostini 1983); andHuang
(n = 29) compared carbenicillin versus azlocillin (Huang 1983).
Unfortunately in these two studies lung function was reported as
part of a composite clinical score and so the only includable data
relate to adverse effects (Agostini 1983; Huang 1983). Caplan (n
= 29) compared cefsulodin to tobramycin or ticarcillin, but again
the only includable data relate to adverse effects (Caplan 1984).
The remaining two studies, Elborn (n = 24) and Salh (n = 22), both
compared ceftazidime to aztreonam (Elborn 1992; Salh 1992).
Primary outcomes
1. Lung function
a. FEV1
Both Elborn and Salh report absolute change in FEV1 (Elborn
1992; Salh 1992); the SDs of mean change were imputed as dis-
cussed previously (Included studies). Neither study identified a
significant difference between the two groups with the pooledMD
also being statistically non-significant, MD -0.12 litres (95%CI -
1.08 to 0.84) (Analysis 3.1).
Secondary outcomes
4. Mortality
In the Caplan study, two participants died; however, from the
clinical data provided it would appear that these deaths could not
be attributed to cefsulodin (Caplan 1984).
5. Adverse effects
a. toxicity and allergy
Agostini reported rates of symptoms of side effects and laboratory
findings in two publications (Agostini 1983). The 1983 paper by
Agostini reports more measures of adverse effects, but appears to
report before the end of the study (Table 1); a further report of the
same study byMastella appears to report from the whole study for
liver, renal and haematological parameters (Agostini 1983). These
data are presented in the additional tables (Table 1; Table 2). It is
difficult to attribute such reports with individual antibiotics with
groups containing so few participants. The authors suggested that
reports of nausea and vomiting with cefsulodin correlated with
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infusion rate and that fever and rash with piperacillin between 10
to 12 days was noticeable. They noted a transient rise in serum
liver transaminases with all antibiotics except for azlocillin; and
eosinophilia with all antibiotics, but particularly with ceftazidime
and piperacillin.
Caplan reported headache in one participant (7.1%) receiving
cefsulodin and transiently raised liver enzymes in two participants
(13%) receiving tobramycin (Caplan 1984).
Huang reported one case of rash in both of the groups (azlocillin
or carbenicillin); also, cases of transient increase in serum liver
enzymes were reported in six of the 14 participants receiving car-
benicillin and in two of the 12 participants in the azlocillin group
(Huang 1983).
b. microbiological - isolation of antibiotic resistant strains, or new
strains of bacteria
Agostini reported rates of emergent strains following treatment
(Table 1). The numbers in each group are small and so it is dif-
ficult to determine trends except that it was uncommon for new
strains to emerging following treatment (Agostini 1983). Caplan
discussed an ’indication’ of increasing resistance to cefsulodin but
did not provide data (Caplan 1984). Both studies report rates of
antibiotic sensitivity following treatment, but not rates of sensitiv-
ity at baseline. In the comparison of ceftazidime and aztreonam,
Salh reported that from a baseline of sensitivity, two out of 12
participants receiving ceftazidime and three out of 14 participants
receiving aztreonamdeveloped an increase inminimum inhibitory
concentration (MIC) above 16 mg/l; and concluded no difference
in rates of resistance between the groups (Salh 1992).
Single IV antibiotic in combination with placebo versus
combination IV antibiotics
Four studies with 189 participants, but reporting data for only
145 participants, considered a single IV antibiotic in combination
with a placebo compared to an active two-agent antibiotic combi-
nation (Macfarlane 1985; Master 2001; McLaughlin 1983; Smith
1999). MacFarlane considered two doses of piperacillin (50 mg/
kg six times daily and 100 mg/kg three times daily) each in com-
bination with tobramycin compared to tobramycin with placebo
(Macfarlane 1985). Master compared tobramycin in combination
with placebo with tobramycin combined with ceftazidime (Master
2001). McLaughlin considered the combination of ticarcillin plus
tobramycin compared with azlocillin plus tobramycin and com-
pared with azlocillin plus placebo (McLaughlin 1983). Smith con-
sidered the combination of azlocillin plus tobramycin compared
with azlocillin plus placebo (Smith 1999).
A further study enrolled 15 participants to compare oxacillin in
combinationwith placebo to a combinationof oxacillin, sisomycin
and carbenicillin (Hyatt 1981).
Each of these studies included attrition bias and two also had
unit of analysis issues (Hyatt 1981; Macfarlane 1985) (see
Characteristics of included studies).
Primary outcomes
1. Lung function
a. FEV1
Two further studies reported absolute change in FEV1 %predicted
for comparisons between azlocillin plus tobramycin and azlocillin
plus placebo (McLaughlin 1983; Smith 1999). A meta-analysis of
these two similar studies (I2 = 0%) demonstrated no significant
difference between the two groups, pooled MD 1.37% (95% CI
-1.50 to 4.23) (Analysis 4.1). Hyatt reported the absolute change
in FEV1 % predicted in the comparison between oxacillin plus
placebo versus oxacillin plus sisomycin plus carbenicillin (Hyatt
1981) and concluded there was a significant difference in favour of
the three-drug combination regimen, MD -9.54% (95% -15.98
to -3.10) (Analysis 4.1). Master reported the absolute change in
FEV1 % predicted in the comparison between tobramycin plus
placebo and tobramycin plus ceftazidime (Master 2001). There
was no statistically significant difference between the two groups,
MD -2.20% (95% CI -6.63 to 2.23) (Analysis 4.1). Analysis of a
pooled estimate of FEV1 (%predicted) involving these four studies
(Hyatt 1981;Master 2001;McLaughlin 1983; Smith 1999) yields
no statistically significant difference between groups -0.89% (95%
CI -3.14 to 1.36) (Analysis 4.1).
MacFarlane reported data for percentage (relative) change in FEV1
% predicted for two doses of piperacillin: 50 mg/kg every four
hours and 100 mg/kg every eight hours (Macfarlane 1985). There
were improvements in lung function in all groups across the study
period, but no significant differences between groups: piperacillin
50 mg/kg, MD -4.20 (95% CI -26.50 to 18.10); and piperacillin
100 mg/kg, MD 7.95 (95% CI -8.78 to 24.68). Even when
piperacillin groups were combined (data not provided in paper
but a pooled MD was computed in the meta-analysis), the result
was not statistically significant, MD - 3.58% (95% CI -9.80 to
16.96) (Analysis 4.2).
b. FVC
Two studies reported the absolute change in FVC% predicted for
comparisons between azlocillin plus tobramycin compared with
azlocillin plus placebo (McLaughlin 1983; Smith 1999). A meta-
analysis of these two studies demonstrated no significant difference
between the two groups, pooled MD 1.18% (95% CI -2.53 to
4.89) (I2 = 0%) (Analysis 4.3).
Hyatt reported the absolute change in FVC % predicted in the
comparison between oxacillin in combination with placebo com-
pared with oxacillin, sisomycin and carbenicillin (Hyatt 1981),
concluding no statistically significant difference between the two
groups, MD -9.32% (95% CI -19.86 to 1.22) (Analysis 4.3). A
meta-analysis of each of these three studies yields no significant
difference between the two groups, pooled MD 0.02% (95% CI
-3.48 to 3.52) (Analysis 4.3).
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MacFarlane reported the percentage (relative) change in % pre-
dicted FVC (Macfarlane 1985). There were improvements in lung
function in all groups across the study period, but no signifi-
cant differences between groups: piperacillin 50 mg/kg, MD -
1.20% (95% CI -15.79 to 13.39); and piperacillin 100 mg/kg,
MD -1.35% (95% CI -18.61 to 15.91) (Analysis 4.4). Even when
piperacillin groups were combined (data not provided in paper
but computed in meta-analysis), the result was not statistically sig-
nificant, pooled MD -1.26% (95% CI -12.40 to 9.88) (Analysis
4.4).
2. Time to next exacerbation
McLaughlin reported on the time to next exacerbation with no
significant difference between groups, MD -7.00 weeks (95% CI
-23.67 to 9.67) (Analysis 4.5). Smith reported a survival analysis
of data for the time to next exacerbation, concluding that at 80
days post admission, only 30% of those receiving the combination
antibiotic regimen had been re-admitted compared to 62% of
those receiving azlocillin alone (ANOVA P < 0.01) (Smith 1999).
Master did not reported any significant difference in the time to
next exacerbation between the two groups: for the single-agent
treatment there were a mean of 173 days and a median (range)
of 107 (44 to 476) days until the next exacerbation; and for the
combination treatment, therewas ameanof 153days and amedian
(range) of 125 days (41 to 417) days until the next exacerbation
(Master 2001).
Secondary outcomes
2. Nutritional status
b. weight
OnlyMcFarlane reported absolute changes in weight during treat-
ment (Macfarlane 1985). There were no significant differences
between groups, either individually, MD -0.72 kg (95% CI -2.65
to 1.21) and MD -0.07 kg (95% CI -1.83 to 1.69), or when both
antibiotic groups and both placebo groups were combined, MD -
0.36 kg (95% CI -1.66 to 0.93) (Analysis 4.6).
4. Mortality
Two studies report there were no deaths (Hyatt 1981;McLaughlin
1983).
5. Adverse effects
a. toxicity and allergy
Macfarlane stated that during the 10 treatment periods with
piperacillin, there were three episodes of sensitivity reactions (all
in the higher-dose group), consisting of nausea, vomiting, pru-
ritic rashes, nocturnal fever, and facial oedema (Analysis 4.7); one
participant withdrew as a result (Macfarlane 1985). Laboratory
studies in all participants were normal throughout the study, ex-
cept for one participant in the piperacillin group who had pyuria
(Macfarlane 1985).
A meta-analysis of total adverse effects reported by two further
studies demonstrated no significant difference between groups
(McLaughlin 1983; Smith 1999), OR 1.08 (95%CI 0.50 to 2.37)
(I2 = 0%) (Analysis 4.8). Two studies reported on ototoxicity with
no cases in either group (Hyatt 1981; Smith 1999). The same
two studies reported on nephrotoxicity with a non-significant dif-
ference between groups, OR 0.63 (95% CI 0.05 to 7.27). Smith
further reported on proteinuria and infusion site irritation, both
which were non-significant OR 0.21 (95% CI 0.02 to 1.89) and
OR 1.62 (95% CI 0.26 to 10.08) respectively. Master reported
on tinnitus on two occasions on one participant in each group
(due on both occasions to inadvertent fast administration of to-
bramycin), OR 1.09 (95%CI 0.15 to 8.06) (Analysis 4.8). Master
also reported on serum adverse effects in terms of serum creati-
nine (Master 2001), OR 4.00 (95% CI-1.38 to 9.38), and serum
NAG, OR 2.10 (95% CI 0.74 to 3.46) concluding that single-
agent treatment was less nephrotoxic (Analysis 4.9).
b. microbiological - isolation of antibiotic resistant strains, or new
strains of bacteria
Five studies reported on this outcome (Hyatt 1981; Macfarlane
1985;Master 2001;McLaughlin 1983; Smith 1999). Hyatt exam-
ined sisomycin resistance and reported no significant change over
time (Hyatt 1981). Macfarlane noted no change in susceptibility
profiles in any group (Macfarlane 1985).Master reported increases
in MIC in both treatment groups that reached significance in the
single-agent group (Master 2001). McLaughlin reported a high
baseline rate of in vitro antibiotic resistance (40%) and an increase
in the proportion of resistant isolates, but there were no differences
between groups (P = 0.13; Fisher’s exact test) (McLaughlin 1983).
Smith reported a significant increase in the proportion of isolates
resistant to either azlocillin, tobramycin or both in the combined
azlocillin plus tobramycin-treated group compared to those who
received only azlocillin (ANOVA P < 0.001) (Smith 1999).
Single agent (no placebo) versus antibiotic combination
Ten studies (345 participants) compared a single IV antibiotic
with a combination of two IV antibiotics. Of these six studies
had unit of analysis issues (BTS 1985; Church 1997; De Boeck
1999; McCarty 1988; Padoan 1987; Wesley 1988). Three studies
investigated the use of combination antibiotic treatment by com-
paring the effect of a single antibiotic with the same antibiotic in
combination with another agent (Conway 1997; McCarty 1988;
Padoan 1987) and six compared a single agent to two different
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antibiotics in combination (Bosso 1988; BTS 1985; De Boeck
1989; De Boeck 1999; Gold 1985; Wesley 1988).
The antibiotics and the combinations used were varied. Single
agents compared with a combination including an additional
antibiotic involved colistin with and without another antibiotic
(Conway 1997) and piperacillin with and without tobramycin
(McCarty 1988). The most commonly investigated antibiotic as
the single agent was ceftazidime which was compared to: cef-
tazidime and sisomycin and piperacillin and sisomycin (Padoan
1987); gentamicin and carbenicillin (BTS 1985); tobramycin and
piperacillin (De Boeck 1989); tobramycin and ticarcillin (Gold
1985; Wesley 1988). Other comparisons involved ceftazidime in
combination with tobramycin compared to meropenem alone
(De Boeck 1999) and aztreonam compared to tobramycin with
azlocillin (Bosso 1988).
Unfortunately for one study clinical outcomes were reported in
terms of a proprietary clinical score and so, although there ap-
peared to be no significant differences between groups, includable
data are not available to be presented in the review (Padoan 1987).
Primary outcomes
1. Lung function
One study did not report data for lung function outcomes in such
a way that we could analyse them; however, it narratively reported
no difference between groups in terms of change in peak expi-
ratory flow rate (BTS 1985). A further study (in abstract form)
narratively reported results with subgroups being classified as “ex-
acerbation” or “electively” treated and stated a significant increase
in vital capacity in both groups in the “exacerbation” group (De
Boeck 1999). McCarty also narratively presented the lung func-
tiondata from the study, reporting that both groupswitnessed sim-
ilar improvement in peak flow, FEV1 and FVC (McCarty 1988).
Similarly, Wesley (another abstract) narratively reported the data
in their study suggesting no difference in “pulmonary function”
between groups at the end of 14 days of treatment (Wesley 1988).
Church reported only mean change in lung function without a
measure of distribution of the data and so we could not include
data from this study. The duration of treatment in the two groups
was also not reported making interpretation difficult (Church
1997).
a. FEV1
One study reported absolute change in absolute values (ml) for
FEV1 finding a statistically significant effect favouring a combi-
nation regimen, MD -160.00 ml (95% CI -309.72 to -10.28)
(Conway 1997) (Analysis 5.1). Two studies reported absolute
change in FEV1 % predicted (De Boeck 1989; Bosso 1988) and
one of these also reported percentage (relative) change in FEV1
% predicted FEV1 (Bosso 1988). Neither found any significant
difference in absolute change between single and combination an-
tibiotic regimens, MD 1.00 (95% CI -8.85 to 10.85) (De Boeck
1989) and MD -4.60 (95% CI -11.57 to 2.37) (Bosso 1988);
when pooled there was also a non-significant result, MD -2.73
(95% CI -8.42 to 2.95) (Analysis 5.2).
A further study reported the percentage (relative) change in ab-
solute FEV1 with (contrary to the interpretation in the paper) a
significant difference between groups favouring the combination
agent regimen,MD -19.60 (95%CI -38.26 to -0.94) (Gold 1985)
(Analysis 5.3).
The remaining study reporting on this outcome found no differ-
ence in lung function tests when comparing ceftazidime with to-
bramycin and ticarcillin, but no data are presented (Wesley 1988).
A meta-analysis using SMDs to analyse all measures of FEV1 in
the three studies with a total of 122 participants demonstrates
a statistically significant effect favouring combination antibiotic
regimens (Bosso 1988; Conway 1997; De Boeck 1989), pooled
SMD -0.38 (95% CI -0.74 to -0.02) with no heterogeneity (I2 =
0%) (Analysis 5.4).
b. FVC
Conway reported FVC in terms of absolute change of absolute val-
ues (Conway 1997) and found a significant difference between the
two groups favouring the combination regimen, MD -470.00 ml
(95% CI -695.76 to -244.24) (Analysis 5.5). Bosso reported FVC
both in terms of absolute change and percentage (relative) change
in FVC% predicted (Bosso 1988). Contrary to the findings in the
paper, there was a statistically significant difference between the
two groups favouring the combination antibiotic regimen in both
absolute change, MD -8.10% (95% CI -15.79 to -0.41) (Analysis
5.6) and percentage (relative) change, MD -10.80% (95% CI -
20.67 to -0.93) (Analysis 5.7).
Ameta-analysis usingpooled SMDs to analyse allmeasures of FVC
from the Bosso and Conway studies (101 participants) demon-
strates a statistically significant effect favouring combination an-
tibiotic regimens, pooled SMD -0.89 (95% CI -1.30 to -0.48)
with no heterogeneity (I2 = 0%) (Analysis 5.8).
2. Time to next exacerbation
De Boeck reported the time to re-admission for all except four
participants (one from each group who had not been re-admitted
at the time of the report and one from each group who died) (De
Boeck 1989). There was no significant difference between the two
groups, MD -1.00 months (95% CI -5.52 to 3.52) (Analysis 5.9).
A second study reported the proportion of participants in each
groupwho required re-admission, IV antibiotics orwhodied in the
three months following treatment (BTS 1985). Analysis showed
a significant difference between the two groups favouring the sin-
gle antibiotic group, OR 0.29 (95% CI 0.12 to 0.74) (Analysis
5.10). Wesley reported the proportion of participants who were
re-admitted within three months of treatment with no difference
between the two groups, OR 1.40 (95% CI 0.26 to 7.58) (Wesley
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1988). A pooled estimate for both studies suggests a significant
effect in favour of single agents, OR 0.43 (95% CI 0.19 to 0.95),
although largely influenced by one study (BTS 1985) and with
substantial heterogeneity (I2 = 60%) (Analysis 5.10).
Secondary outcomes
2. Nutritional status
b. weight
Only one study reported data for percentage weight change which
we could analyse (Gold 1985). Therewas no statistically significant
difference between the two groups, MD -1.30% (95% CI -4.36
to 1.76) (Analysis 5.11).
Conway noted absolute weight changes over time in the two
groups; SDs were not stated and we are unable to impute them
(Conway 1997). The study describes a statistically significant 8%
weight gain from baseline in the combination IV antibiotic group
(P < 0.01) compared to a 3% weight gain in the single IV antibi-
otic arm which was not statistically significant (P = 0.16). A sec-
ond study reported significant mean (SEM) weight gain in both
groups of 4 (1)%, with no difference between the two groups (De
Boeck 1989). In the 1999 abstract the same authors narratively
reported an ANOVA whereby only participants in the combina-
tion agent group gained “significant” weight (P < 0.05) (De Boeck
1999). A further study also reported weight data narratively, with
similar improvements observed in both groups (McCarty 1988).
Finally the BTS study stated there were no significant differences
between groups although both treatment groups gained weight
(BTS 1985).
3. Adherence (all measures)
Conway reported adherence to the two IV antibiotic regimens in
hospitalised participants (Conway 1997). Four participants in the
single antibiotic arm missed between one and five doses, while
two participants in the combination treatment arm missed three
doses of colistin and one participant missed four doses; reasons for
missing doses were stated as the participant not being on the ward
(n = 7), refusal of new IV line towards the end of treatment (n =
5), or leaving hospital on last day of treatment for work or school
reasons. On five occasions no reason was given for missing doses
and on two occasions it was unclear whether the doses had been
given as this was not signed for on the drug chart.
4. Mortality
Three studies reported data we could analyse for this outcome (
Conway 1997;DeBoeck 1989;McCarty 1988). Conway reported
the death of one participant in the combination antibiotic arm;
this participant was understood to have severe “terminal CF” lung
disease (Conway 1997). A second study reported one participant
in each group who died; one in the single agent group died one
month after treatment and one in the combination group died
fourmonths after treatment (DeBoeck 1989). TheMcCarty study
reported there were no deaths in either treatment arm (McCarty
1988). When pooled, results were not statistically significant, RR
0.62 (95% CI 0.09 to 4.37) (Analysis 5.12).
5. Adverse effects
a. toxicity and allergy
Five studies reported on liver enzymes and four had data for the
analysis (Bosso 1988; BTS 1985; Gold 1985;Wesley 1988). Bosso
reported changes in hepatic transaminases with 10 participants in
the single agent group and five in the combination agent group
experiencing elevated serum levels during treatment, but with no
significant difference between groups, OR 4.00 (95% CI 0.88 to
18.26) (Bosso 1988). The BTS study reported the proportion of
participants experiencing a rise in serum liver enzymes with no
difference between the two groups, OR 0.58 (95% CI 0.18 to
1.85) (BTS 1985). Gold reported rises in AST for four out of
17 participants receiving single agent and two out of 13 partic-
ipants receiving combination therapy, but no significant differ-
ence between the groups (Gold 1985).Wesley reported no change
in liver enzymes in either group (Wesley 1988). A pooled analy-
sis of liver effects demonstrate no significant difference between
groups, pooled OR 1.00 (95% CI 0.48 to 2.07) (Analysis 5.13).
Finally, Padoan reported narratively that 20% of participants in
each treatment group experienced an increase in liver enzymes
(Padoan 1987) (Table 3).
Conway documented 37 neurological adverse events for 33 par-
ticipants receiving the single antibiotic regimen, which resulted
in one person withdrawing from the study (Conway 1997). In
the combination antibiotic regimen arm 37 neurological adverse
events were recorded for 36 participants; no change in treatment
was needed as a result (Analysis 5.13).
Incidence of rash was reported by three studies (Bosso 1988;
BTS 1985; McCarty 1988). Bosso reported one participant in the
combination group who developed a rash which was thought to
be due to azlocillin and as such administration of this was stopped
(Bosso 1988). A second study also reported experience of rash with
no difference between groups, OR 1.29 (95% CI 0.11 to 14.86)
(BTS 1985). McCarty reported one participant in the single agent
group who withdrew as a result of a rash (McCarty 1988). A
pooled estimate of the comparison between groups reports no
significant difference between groups, OR 1.15 (95% CI 0.24 to
5.48) (Analysis 5.13).
In two studies, the participants in the combination group who
developed a rash also developed a fever and the participant in
the BTS study additionally reported arthralgia (Bosso 1988; BTS
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1985). McCarty reported that one participant in each group de-
veloped fever at day 13 (each resolved after cessation of antibiotic
treatment), OR 1.14 (95%CI 0.06 to 21.87) (McCarty 1988). Fi-
nally, Padoan reported that seven of 20 participants who received
piperacillin developed a fever between 9 and 14 days of treatment
(Padoan 1987).
The BTS study reported that four participants in the combina-
tion group developed thrombophlebitis (and none in the single-
agent group); however, differences between groups did not reach
statistical significance, OR 0.06 (95% CI 0.00 to 1.21) (Analysis
5.13). The BTS study also reported that one participant in the
combination group “developed severe asthma” after one dose and
so was withdrawn from the study (BTS 1985).
Proteinuria was reported in one participant in each group byGold,
OR 1.00 (95% CI 0.06 to 17.41) (Gold 1985).
In terms of renal toxicity, Conway noted statistically significant
rises in blood urea and significant falls in creatinine clearance in
both groups; however, there was no statistically significant differ-
ence between groups for either outcome (Analysis 5.14). Padoan
reported that no changes in renal function were observed (Padoan
1987) (Table 3).
b. microbiological - isolation of antibiotic resistant strains, or new
strains of bacteria
One study reported that those participants with antibiotic-resis-
tant P. aeruginosa and B. cepacia responded as well to treatment
as those with antibiotic-sensitive strains (as determined by their
proprietary clinical score) (Bosso 1988). The number of partici-
pants with resistant isolates increased with treatment with an ad-
ditional five out of 14 participants, three out of 14 and none out of
14 participants isolating strains of P. aeruginosa resistant to aztre-
onam, tobramycin and azlocillin respectively (Analysis 5.15). The
number of participants with resistant strains returned to baseline
at follow up.
WhileGold noted no correlation between clinical and bacteriolog-
ical outcomes when reporting greater reductions in P. aeruginosa
colony counts with the ceftazidime-treated group (single agent),
the emergence of antibiotic resistance, as defined by a greater than
two-fold increase in theMIC to the administered agents, occurred
more frequently in those receiving the combination agent regimen
(Gold 1985); one out of 39 participants in the single-agent group
and seven out of 23 participants in the combination-agent group
(Analysis 5.15). A pooled effect estimate including three studies
(Bosso 1988; Gold 1985; McCarty 1988) suggests no statistically
significant effect, OR 0.42 (95% CI 0.14 to 1.24), although with
considerable heterogeneity (I2 = 84%) (Analysis 5.15).
The BTS study reported the acquisition of antibiotic resistance
to each of the antibiotics administered (BTS 1985). Two out of
35 participants receiving ceftazidime, three out of 29 receiving
gentamicin and three out of 26 receiving carbenicillin isolated an-
tibiotic-resistant P. aeruginosa strains following treatment. Com-
paring the proportion of participants isolating antibiotic-resistant
strains in the single-agent (ceftazidime) group with the combina-
tion group consisting of gentamicin and carbenicillin there were
no differences between the comparisons, OR 0.53 (95% CI 0.08
to 3.38) and OR 0.46 (95% CI 0.07 to 3.00) respectively (Anal-
ysis 5.15).
The development of antibiotic resistance was not witnessed in any
participant in the McCarty study (McCarty 1988).
Padoan reported that the proportion of strains that were resistant
to ceftazidime increased from 4% to 37% in both single and com-
bination arms, although rather than returning to baseline after
treatment, as was observed in the single-agent arm, the propor-
tion of isolates resistant to ceftazidime remained high (30%) in
the combination group (Padoan 1987) (Table 3).
All-group single agent versus combination treatment
1. Lung function
Ameta-analysis including eight studies with low heterogeneity for
which we were able to present data comparing single-agent with
combination-agent treatment did not show a statistically signifi-
cant difference in FEV1, pooled SMD -0.21 (95%CI -0.42, 0.01)
(Analysis 6.1). However, when we consider individual measures
of reported FEV1 we find that the better quality studies reporting
absolute and relative changes in FEV1 % predicted show no sig-
nificant difference between single and combination treatment: ab-
solute change in FEV1 % predicted, MD -1.14% (95% CI -3.23
to 0.95) (Analysis 6.3); relative change in FEV1 % predicted, MD
3.58% (95% CI -9.80 to 16.96) (Analysis 6.5); absolute change
FVC % predicted MD -1.37 (95% CI -4.56 to 1.81) (Analysis
6.7). Ameta-analysis of five studies withmoderate levels of hetero-
geneity favoured combination-agent treatment for FVC, pooled
SMD -0.44 (95% CI -0.71 to -0.16) (Analysis 6.6).
Combination IV antibiotic regimens compared
Nine studies, recruiting 417 participants, compared two com-
binations of two IV antibiotics (Blumer 2005; Conway 1985;
McLaughlin 1983; Penketh 1983; Penketh 1984; Schaad 1986;
Schaad 1989; Semykin 2010; Wang 1988). Again the IV an-
tibiotics used were varied. Two studies administered a combina-
tion of netilmicin and ticarcillin, but used different comparators:
tobramycin and ticarcillin (Conway 1985) and netilmicin and
azlocillin (Schaad 1986). Two studies by the same lead author com-
pared carbenicillin and gentamicin to other IV antibiotic combi-
nations - ticarcillin and gentamicin (Penketh 1983) and azlocillin
and gentamicin (Penketh 1984). In one study, in addition to the
two arms comparing azlocillin and placebo with azlocillin and to-
bramycin, McLaughlin also compared these with a combination
of ticarcillin and tobramycin, a comparison we include in this
section (McLaughlin 1983). A further study also undertook this
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comparison with an additional arm comprising of oral ciprofloxa-
cin (Wang 1988).We include the azlocillin and tobramycin versus
tobramycin and ticarcillin comparison in this section. One study
with an arm involving the administration of oral and nebulised an-
tibiotics, also compared cefipime and amikacin with meropenem
and amikacin (Semykin 2010). The remaining two studies com-
pared meropenem and tobramycin versus ceftazidime and to-
bramycin (Blumer 2005) and aztreonam and amikacin versus cef-
tazidime and amikacin (Schaad 1989).
Primary outcomes
1. Lung function
The Conway study narratively reported significant improvements
in lung function, but did not report a comparison between groups,
reporting only data for PEFR (Conway 1985). Similarly, Wang
narratively reported “favourable results” in lung function in the
two arms that consisted of combination intravenous antibiotics,
but with no difference between the two groups (Wang 1988). A
third study reported percentage (relative) changes in FEV1 and
FVC in the two intravenous regimen groups; however, they do
not report appropriate data for a comparison between groups (
Semykin 2010).
a. FEV1
For the Blumer study, which compared tobramycin administered
in combination with either ceftazidime or meropenem (Blumer
2005), we imputed change in terms of absolute change in % pre-
dicted FEV1 for potential future use in a meta-analysis; the re-
sult was not statistically significant, MD 2.70% (95% CI -0.76
to 6.16) (Analysis 7.1). In the publication, Blumer reported the
percentage (relative) change from baseline of % predicted FEV1;
analysis showed that there was no significant difference between
the two groups, MD 9.40% (95% CI -8.44 to 27.24) (Analysis
7.2).
Two studies reported the absolute change in FEV1 % predicted
(McLaughlin 1983; Schaad 1989). McLaughlin compared to-
bramycin in combination with either azlocillin or ticarcillin and
our analysis found no significant difference between the two
groups,MD-3.00%(95%CI -8.75 to 2.75) (Analysis 8.1). Schaad
compared aztreonam with amikacin to ceftazidime with amikacin
and showed no significant difference between the two groups in
absolute change in FEV1 % predicted at the end of intravenous
therapy, MD 4.00% (95% CI -0.25 to 8.25) (Analysis 11.1).
The later Penketh study reported absolute values inFEV1 (Penketh
1984). We imputed the SD of the mean change and detected no
significant difference between the two groups in absolute change
in FEV1, MD 51.00 ml (95% CI -358.68 to 460.68) (Analysis
9.1).
Penketh’s 1983 study reported the change in FEV1, with statisti-
cally significant improvements from baseline in each group; how-
ever, they do not provide data to allow us to perform a between-
group comparison and they report no statistically significant dif-
ferences between the groups (Penketh 1983).
b. FVC
The two studies by Schaad reported absolute change in FVC %
predicted (Schaad 1986; Schaad 1989). Neither study found a
significant difference between the two groups at the end of the
IV therapy, MD 2.00% (95% CI -5.48 to 9.48) (Schaad 1986)
(Analysis 10.1) and MD 2.00% (95% CI (-5.17 to 9.17) (Schaad
1989) (Analysis 11.2).
The later Penketh study reported absolute change inFVC (Penketh
1984). Following the imputation of the SD of the change, we
foundno significant difference between the twogroups,MD74.00
ml (95% CI -410.48 to 558.48) (Analysis 9.2).
The earlier Penketh report does not provide data to allow us to
analyse the change in absolute FVC. It reports statistically signif-
icant improvements from baseline in each group, but no data to
allow us to perform a between-group comparison; the differences
between groups were not statistically significant (Penketh 1983).
2. Time to next exacerbation
One study reported an extended follow-up period of two to four
weeks after discontinuation of therapy and during this time 33
participants in the meropenem group and 38 participants in the
ceftazidime group received treatment for an exacerbation (median
period of 176 days and 207 days respectively) (Blumer 2005). Our
analysis shows that this difference did not meet statistical signifi-
cance, OR 0.72 (95% CI 0.31 to 1.67) (Analysis 7.3). McLaugh-
lin reported time-to-next exacerbation data in weeks (McLaughlin
1983); there was no significant difference between the two groups,
MD -6.00 weeks (95% CI -17.27 to 5.27) (Analysis 8.2).
In the 1983 study, Penketh reported a statistical test finding no
significant difference between groups in the time to next admis-
sion due to an exacerbation; five participants in the carbenicillin
group were re-admitted on average 5.4 months following treat-
ment, compared to three participants in the ticarcillin group being
re-admitted on average 3.5 months following treatment (Penketh
1983). Similarly, in the later study, Penketh reported the time to
next exacerbation during the period of time since the study com-
pleted to the time of reporting (Penketh 1984). The study found
that five participants in the azlocillin group were re-admitted on
average four months following treatment compared to five partic-
ipants in the carbenicillin group being re-admitted on average 3.6
months following treatment; this difference was not statistically
significant.
Secondary outcomes
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2. Nutritional status
b. weight
Conway reported percentage change in weight over the study pe-
riod with significant gains in weight in both groups (3.2% and
3.1% netilmicin and tobramycin respectively), but does not com-
ment upon differences between groups (Conway 1985). Both
Schaad studies also report on weight as percentage underweight;
in neither study were the differences significant (Schaad 1986;
Schaad 1989).
4. Mortality
Two studies reportednodeaths in in the first threemonths (Blumer
2005; McLaughlin 1983); although McLaughlin did further re-
port 10 deaths in the subsequent 18 months (McLaughlin 1983).
In the 1984 study, Penketh reported the death of one participant
in the azlocillin groupwho did not respond sufficiently to go home
and who later died (Penketh 1984), at 12-month follow up RR
3.00 (95% CI 0.14 to 65.90) (Analysis 9.3).
5. Adverse effects
a. toxicity and allergy
Two studies included general statements that they had observed
no evidence of toxicity (Penketh 1984; Wang 1988). A further
study reported treatment-related adverse effects in 21 (40.4%) of
participants in the ceftazidime group compared with 19 (38%) of
those in the meropenem group (Blumer 2005).
Three studies commented on liver-related adverse events (Penketh
1983; Schaad 1986; Schaad 1989). In the earlier study, Schaad
reported significant reductions in serum alkaline phosphatase in
both groups, but do not report a group-wise analysis (Schaad
1986). They also reported no significant differences between
groups in liver transaminase elevation, OR 1.58 (95% CI 0.24
to 10.60) (Analysis 10.2). In the 1989 study, Schaad reported
analysable data for elevated liver enzymes, but this was not signif-
icant, OR 7.82 (95% CI 0.39 to 158.87) (Analysis 11.3). Pen-
keth reported no evidence of hepatic toxicity in any participant
(Penketh 1983).
Four studies commented on renal toxicity (Conway 1985; Penketh
1983; Schaad 1986; Schaad 1989). Conway reported normal re-
nal function (urea, creatinine and electrolytes) although serum
NAGdid suggest renal tubular damage in all participants (Conway
1985). Penketh reported no evidence of renal toxicity in any par-
ticipant (Penketh 1983). Renal function was monitored in both
Schaad studies; the earlier one stated there were no changes with
treatment (Schaad 1986) and the later one reported no significant
changes in renal function (Schaad 1989).
Three studies commented on ototoxicity (Conway 1985; Schaad
1986; Schaad 1989). The earlier Schaad study stated no inci-
dences of regimen-induced ototoxicity were found. The later study
also examined hearing and found no change in any participants
(Schaad 1989). Conway reported normal audiograms in all par-
ticipants (Conway 1985).
One study reported phlebitis in three participants, but without
detailing the groups to which these participants were assigned
(Schaad 1986).
Both Schaad studies commented on skin rash; the earlier one stated
that one participant in each group had urticaria (Schaad 1986)
and the later one supplied data for the analysis, OR 0.19 (95% CI
0.01to 4.05) (Analysis 11.3).
The later Schaad study also reported no difference between groups
in the proportions of participants experiencing thrombocytopenia,
OR 7.82 (95%CI 0.39 to 158.87) (Schaad 1989) (Analysis 11.3).
b. microbiological - isolation of antibiotic resistant strains, or new
strains of bacteria
Blumer reported the isolation of antibiotic-resistant strains to the
antibiotics under examination (Blumer 2005). The study found
a decrease from baseline in the number of participants isolating
resistant strains at the end of treatment, but no significant differ-
ence between groups, OR 0.35 (95% CI 0.01 to 8.74) (Analysis
7.4). This decrease in isolation returned to baseline at follow up.
McLaughlin reported antibiotic susceptibility at baseline and at
end of treatment with one participant acquiring ticarcillin resis-
tance and two acquiring tobramycin resistance in the ticarcillin
group compared with three participants acquiring azlocillin re-
sistance and none acquiring tobramycin-resistant strains during
treatment in the azlocillin group (McLaughlin 1983). Analysed
per regimen, there were no differences between the groups, OR
1.10 (95% CI 0.18 to 6.76) (Analysis 8.3).
While the earlier Schaad study reported S. aureus andH. influenzae
in pre-treatment cultures, there were no non-Pseudomonas isolates
present at the end of treatment (Schaad 1986). In terms of P.
aeruginosa resistance, resistance to netilmicin was not analysed by
group but was found to have reduced during treatment; however,
resistance to azlocillin increased fromnine out of 37 to eight out of
25 strains in this group compared to nine out of 37 with ticarcillin
resistance at baseline and five out of 25 at end of treatment in this
group. This difference was not statistically significant, OR 0.91
(95% CI 0.40 to 2.09) (Analysis 10.3).
Finally, the later Schaad study reported that the emergence of
resistance with treatment was not significant, but that there was no
significant association between bacteriologic response and clinical
or laboratory findings (Schaad 1989).
IV antibiotic regimen versus nebulised antibiotics
A total of five studies with 235 participants compared an IV an-
tibiotic regimen to nebulised antibiotics (Cooper 1985; Knowles
1988; Schaad 1987; Semykin 2010; Stephens 1983). Unfortu-
nately one of these studies compared two IV regimens with a reg-
imen consisting of a combination of an IV, an inhaled and an
oral antibiotic and so it is difficult to attribute any change to the
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addition of either the oral or inhaled treatment (Semykin 2010).
Types of antibiotic varied among studies. One study compared an
IV antibiotic regimen with an inhaled antibiotic regimen using
IV tobramycin and ticarcillin compared to inhaled tobramycin
and inhaled carbenicillin (Cooper 1985). Four studies investi-
gated the effect of inhaled antibiotics as an adjunct to IV antibi-
otic use (Knowles 1988; Schaad 1987; Semykin 2010; Stephens
1983). Knowles compared IV piperacillin and IV tobramycin to
IV piperacillin and IV tobramycin with the addition of these
same antibiotics delivered by nebuliser (Knowles 1988). Simi-
larly, Stephens compared IV ticarcillin plus IV tobramycin to IV
ticarcillin plus IV tobramycin with the addition of inhaled to-
bramycin (Stephens 1983). Schaad compared IV ceftazidime and
IV amikacin to IV ceftazidime and IV amikacin with the addi-
tion of inhaled amikacin (Schaad 1987). As mentioned above, the
fourth study to compare IV antibiotics to nebulised antibiotics
compared IV cefepime with IV amikacin to IV meropenem and
IV amikacin and also to inhaled tobramycin given alongside IV
ceftazidime and oral ciprofloxacin (Semykin 2010).
Primary outcomes
1. Lung function
a. FEV1
One study reported FEV1 in % predicted before and after treat-
ment and a further study reported changes in FEV1 % predicted;
neither study provided sufficient data to allow for contribution to
a meta-analysis, but stated that there were no significant differ-
ences between the two groups (Cooper 1985; Stephens 1983). A
third study reported improvements in both groups during treat-
ment, although there was no difference between groups in terms
of FEV1 (Knowles 1988).
b. FVC
In the 1987 study, Schaad reported change in absolute values of
FVC% predicted in their comparison of regimens with and with-
out inhaled amikacin (Schaad 1987). Using imputed SDs of the
measure of change, there were no significant differences between
the two groups, MD 0.00% (95% CI -3.94 to 3.94) (Analysis
12.1).
Two further studies commented on FVC, but did not provide
data suitable to enter into an analysis (Cooper 1985; Knowles
1988). The first reported FVC in % predicted before and af-
ter treatment and found no significant difference between groups
(Cooper 1985). The second study reported improvements in both
groups during treatment, although there was no difference be-
tween groups (Knowles 1988).
Secondary outcomes
2. Nutritional status
b. weight
One study reported that only the group receiving IV and inhaled
antibiotics significantly gained weight during treatment, although
there were no differences between the groups (Knowles 1988). A
second study reported change in bodyweight during treatment and
cited no significant differences between the two groups (Stephens
1983). Schaad reported the effect of the compared regimens in
terms of percentage underweight and suggested no significant dif-
ference between the two groups (Schaad 1987).
5. Adverse effects
a. toxicity and allergy
Schaad reported the proportions of participants experiencing
raised liver enzymes (Schaad 1987), but there were no significant
differences between the two groups, OR 0.60 (95% CI 0.16 to
2.27) (Analysis 12.2).
Two studies commented on renal toxicity; one stated that no renal
toxicity was observed (Stephens 1983) and the second that there
were no significant changes in renal function (Schaad 1987).
Schaad also stated that there were no significant changes in au-
diometry; but that transient haematologic abnormalities occurred
in eight participants (eosinophilia, neutropenia and thrombocy-
topenia), although this was not analysed by group (Schaad 1987).
b. microbiological - isolation of antibiotic resistant strains, or
new strains of bacteria
Schaad noted an increase in ceftazidime- and amikacin-specific
antibiotic resistance in both groups under comparison, although
from the data provided it is not possible to detect a significant dif-
ference between groups (Schaad 1987). The study noted no sig-
nificant association between microbiology parameters and clinical
response.
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IV antibiotic regimen versus oral antibiotics
A total of seven studies with 450 participants compared an IV
antibiotic regimen to a regimen that contained oral antibiotics
(Black 1990; Bosso 1989; Church 1997; Hodson 1987; Richard
1997; Semykin 2010; Wang 1988). As already stated, Semykin
compared two IV regimens with a regimen consisting of a com-
bination of an IV, an inhaled and an oral antibiotic, and so it is
difficult to attribute any change to the addition of either the oral
or inhaled treatment (Semykin 2010).
Four studies compared oral ciprofloxacin with two-agent IV com-
binations (Bosso 1989;Hodson 1987;Richard 1997;Wang 1988).
Of these, one study compared oral ciprofloxacin to IV azlocillin
with gentamicin (Hodson 1987); another compared it to IV cef-
tazidime with tobramycin (Richard 1997); a third compared it
to IV tobramycin with azlocillin (Bosso 1989); and the remain-
ing study had a three-arm comparison of oral ciprofloxacin to IV
tobramycin with azlocillin and to IV tobramycin plus ticarcillin
(Wang 1988). A further study compared oral ciprofloxacin with
oral ciprofloxacin cycledwith IV tobramycin with azlocillin (Black
1990). Church compared single agent IV ciprofloxacin followed
by single agent oral ciprofloxacinwith combination treatmentwith
IV tobramycin and IV ceftazidime with multiple reporting peri-
ods, thus comparing both single with combination IV agents and
oral compared with IV (Church 1997).
Of the two studies comparing oral ciprofloxacin with tobramycin
plus azlocillin, one was a more completely reported study in two
publications (Bosso 1989) and the second was reported in abstract
form only (Wang 1988). The Bosso publications contained some
uncertainty regarding the reporting of those who withdrew from
the study (Characteristics of included studies); the authors report
an analysis suggesting that, for a number of variables, the charac-
teristics at admission of those who completed the protocol were
not statistically significantly different from compared to those that
did not (Bosso 1989). There were also significant unit of anal-
ysis issues in the Wang study, the results of which are reported
narratively with all three regimens improving, but no significant
differences between the treatment arms.
Primary outcomes
1. Lung function
Black measured lung function but this was unfortunately not re-
ported in detail, instead reporting that “clinical efficacy” was the
same (Black 1990). Church reported only mean change in lung
function without a measure of distribution of the data and so we
could not include data from this study. The duration of treatment
in the two groups was also not reported making interpretation
difficult (Church 1997).
a. FEV1
Three studies reported on FEV1 (Bosso 1989; Hodson 1987;
Richard 1997). Bosso (n = 24) reported the absolute change in
FEV1%predicted and found no significant difference between the
two groups, MD 1.40% (95% CI -4.43 to 7.23) (Analysis 13.1).
Hodson (n = 40) reported absolute changes in absolute values of
FEV1, although this did not reach statistical significance,MD0.11
litres (95% CI -0.14 to 0.37) (Analysis 14.1). Finally, Richard (n
= 108) reported the percentage (relative) change in FEV1 with-
out measures of distribution, but stated comparable changes from
baseline in the two groups (Richard 1997). A pooled estimate of
effect involving two studies yields no statistically significant differ-
ence, SMD -0.24 (95% CI -0.73 to 0.25) (Bosso 1989; Hodson
1987) (Analysis 16.1).
b. FVC
Three studies reported on FEV1 (Bosso 1989; Hodson 1987;
Richard 1997). Bosso reported the absolute change in FVC %
predicted and found no significant difference between the two
groups, MD 2.00% (95% CI -7.50 to 11.50) (Analysis 13.2).
Hodson reported the absolute changes in absolute values of FVC,
reporting no statistically significant difference between the groups,
MD 0.26 litres (95% CI -0.06 to 0.57) (Analysis 14.2). Similar to
that with FEV1, Richard reported the percentage (relative) change
in FVC without measures of distribution, reporting comparable
changes from baseline in both groups (Richard 1997). A pooled
estimate of effect involving two studies yields no statistically sig-
nificant difference, SMD -0.24 (95% CI -0.74 to 0.26) (Bosso
1989; Hodson 1987) (Analysis 16.2) .
2. Time to next exacerbation
Only Richard reported on this outcome (Richard 1997). There
were nine participants in the ciprofloxacin group and five in the
combined IV groups who had a pulmonary exacerbation between
nine and 30 days after the end of initial treatment with no signif-
icant difference between the groups, OR 1.88 (95% CI 0.59 to
6.03) (Analysis 15.1).
Secondary outcomes
4. Mortality
Only Hodson (n = 40) reported on mortality at six weeks and at
three months (Hodson 1987). One participant who received oral
ciprofloxacin died within six weeks of treatment, one further par-
ticipant in this group died within the first three months. One par-
ticipant who received combination IV treatment also died within
the first three months. Overall this was not significantly different
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across the two groups at either six weeks, RR 0.33 (95% CI 0.01,
7.72) or three months, RR 1.00 (95% CI 0.07 to 14.90) (Analysis
14.3).
5. Adverse effects
a. toxicity and allergy
Richard (n = 108) reported treatment-related adverse effects with
no significant differences between the two groups, OR 0.84 (95%
CI 0.31 to 2.27) (Analysis 15.2). The study by Hodson (n = 40)
reported one participant in the combination IV treatment group
who developed mild anorexia and malaise while three participants
in the oral ciprofloxacin group reported side effects - tiredness,
vague aches and pains and mild diarrhoea (one each) (Hodson
1987). A further study (n = 16) reported one participant withdrew
from the study due to diarrhoea and three participants with pho-
tosensitivity (Black 1990). Two studies reported that no drug side
effects were experienced in the study period (Bosso 1989; Wang
1988).
b. microbiological - isolation of antibiotic resistant strains, or
new strains of bacteria
Hodson reported that three participants in the azlocillin plus gen-
tamicin group had organisms resistant to these antibiotics at day
10 (for two of these participants later profiles returned to full sensi-
tivity within six weeks), while two participants in the ciprofloxacin
group had organisms resistant to this antibiotic (both of which re-
turned to full sensitivity by six weeks) (Hodson 1987). One study
reported that weekly sputum cultures did not identify emergence
of resistance to ciprofloxacin (Wang 1988); and a further study
reported no change in antibiotic susceptibility patterns (Richard
1997). Finally, Black did not report MIC breakpoints; however,
they noted that MICs rose during treatment, but returned to pre-
treatment levels after treatment was stopped (Black 1990).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Nebulised antibiotics compared to IV antibiotics for pulmonary exacerbations in people with cystic fibrosis
Patient or population: people with cyst ic f ibrosis experiencing a pulmonary exacerbat ion
Settings: inpat ients (hospital)
Intervention: nebulised ant ibiot ics
Comparison: IV ant ibiot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
IV antibiotics Nebulised antibiotics
FVC (% predicted) ab-
solute change
Follow up: 14 days
The mean absolute
change in FVC
(%predicted) in the con-
trol group was 13%
The mean absolute
change in FVC (% pre-
dicted) in the interven-
t ion groups was not dif -
ferent
0% (3.94 lower to 3.94
higher)
54 (1 study)(Schaad
1987)
⊕©©©
very low1,2,3
The assumed risk rep-
resents the mean of ef -
fect observed in the IV
ant ibiot ics group and
corresponding risk that
of the result of the
meta-analysis with re-
spect to the nebulised
ant ibiot ics group
Quality was determined
by downgrading by one
point based on the
low numbers of events
and downgraded fur-
ther due to a lack of
blinding
Time to next exacerba-
t ion
Not reported
Quality of lif e Not reported
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* The authors calculated the assumed risk as the mean of the ef fect size of the control group in each study. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; FVC: f orced vital capacity; IV: intravenous
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias; the study was either unblinded or single blind.
2 Downgraded one level due to the low numbers of events observed in the studies.
3 Downgraded one level for risk of bias with no information on blinding or randomisat ion methods used.
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Oral antibiotics compared to intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis
Patient or population: people with cyst ic f ibrosis experiencing a pulmonary exacerbat ion
Settings: inpat ients (hospital)
Intervention: oral ant ibiot ics
Comparison: intravenous ant ibiot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
IV antibiotics Oral antibiotics
FEV1 (% predicted) ab-
solute change
Follow up: 7 - 14 days
The mean absolute
change in FEV1 (% pre-
dicted) in the control
group was 5.8%
The mean absolute
change in FEV1 (% pre-
dicted) in the interven-
t ion group was
1.4% lower
(7.23 lower to 4.43
higher)
24 (1 study)
(Bosso 1989)
⊕⊕©©
low1,2
The assumed risk rep-
resents the mean of ef -
fect observed in the IV
ant ibiot ics group and
corresponding risk that
of the result of the
meta-analysis with re-
spect to the oral ant ibi-
ot ics group
Quality was determined
by downgrading by one
point based on the
low numbers of events
and downgraded fur-
ther due to a lack of
blinding
FVC (% predicted) ab-
solute change
Follow up: 7 - 14 days
The mean absolute
change in FVC (% pre-
dicted) in the control
group was 6.6%
The mean absolute
change in FVC (% pre-
dicted) in the interven-
t ion group was
2% higher
(7.5 lower to 11.5
24 (1 study)
(Bosso 1989)
⊕⊕©©
low1,2
The assumed risk rep-
resents the mean of ef -
fect observed in the IV
ant ibiot ics group and
corresponding risk that
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higher) of the result of the
meta-analysis with re-
spect to the oral ant ibi-
ot ics group
Quality was determined
by downgrading by one
point based on the
low numbers of events
and downgraded fur-
ther due to a lack of
blinding
Time to next exacerba-
t ion
Not reported
Quality of lif e Not reported
* The authors calculated the assumed risk as the mean of the ef fect size of the control group in each study. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; FEV1 : f orced expiratory volume at one second; FVC: f orced vital capacity; IV: intravenous
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias; the study was either unblinded or single blind.
2 Downgraded one level due to the low numbers of events observed in the studies.
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D I S C U S S I O N
We identified 40 studies that considered the role of intravenous
(IV) antibiotics for the treatment of pulmonary exacerbations in
people with cystic fibrosis (CF). In these studies 1717 participants
were recruited, with data available for 1054 participants. The qual-
ity of these studies were variable; however, the majority were small
studies with an unclear or high risk of bias. Eight studies were
reported in conference abstract format only.
Summary of main results
Overall, antibiotics appear to be largely well-tolerated; however,
transient self-limiting mild side effects are encountered by many
participants.
IV antibiotics versus placebo
Three small studies (63 participants) considered the use of IV an-
tibiotics compared to placebo. One study did not report sufficient
data to allow for contribution to a meta-analysis, the reporting
of another contained a typographical error precluding its use and
the final study required the use of graphical software to extract
the data from graphs presented. These studies had conflicting re-
sults.There was no effect upon weight detected in the two studies
which considered this outcome.
Single agent versus combination agent IV treatment
Four studies with a placebo-containing group and 10 without,
compared the effect of single versus combination IV antibiotic
treatment (Summary of findings for the main comparison). A
meta-analysis of SMD for bothmeasures of lung function for those
studies which included a placebo agent suggested no difference
between treatment groups, while the comparison of those studies
without a placebo agent was statistically significant in favour of
combination antibiotic treatment. A similar meta-analysis consid-
ering FVC all those studies comparing a single versus a combina-
tion of agents also yielded a statistically significant effect favouring
combination treatment. All studies whichmeasured weight, found
no difference between groups except for one which reported sta-
tistically significantly improved weight gain in those treated with
combination IV antibiotics (De Boeck 1989). In terms of time to
next exacerbation, all those studieswhich reported on this outcome
found no significant difference except for one which reported a
statistically significant effect in favour of single agent treatment
(BTS 1985).
Combination agents compared
There is considerable variation in the combinations of agents com-
pared, with nine studies recruiting 417 participants which admin-
istered eight antibiotics in nine different antibiotic combinations.
However, no combination agent was found to have a statistically
significantly different effect to any other for any outcomemeasure.
IV versus nebulised antibiotics
Five studies (235 participants) compared an IV antibiotic regimen
to nebulised antibiotics with no significant differences between
groups in terms of lung function or weight (Summary of findings
2).
IV versus oral antibiotics
Five studies (320 participants) compared an IV antibiotic regimen
to a regimen that contained oral antibiotics with no statistically
significant difference between the two treatment groups in terms
of lung function, time to next exacerbation ormortality (Summary
of findings 3).
Overall completeness and applicability of
evidence
Many of the studies are old (28 studies reporting prior to 1990)
with only three studies being reported since 2000. Many com-
panion treatments have been introduced over this period and the
outcomes of those with CF have improved considerably. The gen-
eralisability of the results of older studies to clinical practice en-
countered today could therefore be questioned.
It is disappointing that participant-reported outcomes have been
excluded from the literature to date (accepting that the evolution
of such outcomes has been relatively recent compared to the era
of these trials) and adherence was considered in only one study.
While we accept that there is no agreed definition of what consti-
tutes a pulmonary exacerbation, we used a broad definition (and
one that appears to be used in clinical practice) and do not think
that this will impact the evidence found in the review. Also, we
believe that each outcome is relatively equally represented in terms
of participant mix, allowing the results to be applied to the wider
CF population.
Quality of the evidence
Many studies include inherent methodological weaknesses, the
classification of which is often difficult due to inadequate detail
in the reporting of their methods. A significant challenge for this
body of evidence and reasons for the determination of the low
quality of evidence lies in the imprecision inherent in the large
number of very small studies with low numbers of events.Many
of which fail to report a power calculation. As such it is difficult
to assess whether these studies were sufficiently powered to detect
a difference, should one exist. Another common reason for down-
grading the quality of evidence presented was due to risk of bias
introduced by unit of analysis issues, whereby participants are re-
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recruited to the study and, by definition, more unwell participants
contribute data on numerous occasions. Intention-to-treat anal-
yses with the participant as the unit of analysis would overcome
these issues, but such analyses are rare in the studies eligible for
inclusion in this review. It is therefore disappointing that we have
been unable to perform subgroup analyses by severity of lung dis-
ease, as was planned, in order to consider whether the effect of
treatment is greatest in those with most to gain or whether those
with minimal lung disease are more sensitive to treatment.
Potential biases in the review process
No potential biases in the review process were identified. All au-
thors documented their a priori opinions regarding the effective-
ness of IV antibiotics for the treatment of pulmonary exacerba-
tions:
MH: I think that IV antibiotics are likely to be beneficial in the
treatment of some CF pulmonary exacerbations; however the fact
thatmany people fail to regain their baseline lung function suggests
that IV antibiotics are currently being used sub-optimally and are
perhaps not the whole answer for all people with CF.
AP: I think that IV antibiotics are beneficial for the treatment
of pulmonary exacerbations. I think that teasing apart the effects
of IV antibiotics (which are often delivered in hospital) and the
effects of the hospital admission itself (frequent review, intensive
physiotherapy dietetic and nursing input) will be difficult.
PF: I believe that antibiotics are beneficial in the treatment of CF
pulmonary exacerbations. The need for IV antibiotics is primarily
based upon the limitations of the drug formulation (i.e. only avail-
able in IV form). My prediction is that the literature will provide
insufficient information regarding the benefit of IV antibiotics for
several reasons:
1. there are few studies consisting of few participants;
2. we have a poor definition of a pulmonary exacerbation and
must accept that there are different causes of worsening
symptoms leading to the intervention;
3. any study will already be biased to demonstrate a benefit as
those who are “less ill” will likely be treated with another form of
therapy (e.g. oral antibiotics, inhaled antibiotics, dornase alfa).
Agreements and disagreements with other
studies or reviews
No other systematic reviews addressing the study question have
been identified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the poor quality of evidence, the results are not conclusive.
The principle of treating people with pulmonary exacerbations
with IV antibiotics is based largely on clinical experience and cur-
rent guidance largely recommends combination antibiotic treat-
ment for reasons of antibiotic resistance. The quality of the stud-
ies included in this review is poor and while no effect on antibi-
otic resistance was observed, differences in lung function between
combination treatment compared to single agent regimens were
only seen in the inclusive meta-analysis with no effect observed in
the more restrictive analyses. There appears to be no evidence to
recommend the use of any particular IV antibiotic combination
over another; and no evidence to suggest that any route of antibi-
otic administration is superior to any other.
Implications for research
Questions remain regarding the use of IV antibiotics for people
with CF experiencing pulmonary exacerbations, an event that for
many people results in a significant loss of lung function that is not
regained (Sanders 2010). While there is unlikely to be equipoise
in the use of antibiotics for pulmonary exacerbations per se, the
appropriate route of such antibiotics may be open to enquiry, par-
ticularly for those with mild disease, with the potential attendant
reductions in burden of treatment that would accompany a non-
parenteral route of administration. Ideally, to answer the question
of the use of IV antibiotics to treat pulmonary exacerbations, a
double-blind randomised placebo-controlled trial recruiting both
adults and children with CF to receive combination antibiotics
versus placebo would be needed. Debate is fierce regarding appro-
priate outcomes to be measured. As is the case in this review, lung
function is an outcome of interest but is difficult to interpret and
furthermore standardised timing of measurement is an issue. The
time to next exacerbation is considered by many to be a meaning-
ful outcome, but it is often distant in time from the intervention
and so difficult to attribute exclusively. Amore pragmatic outcome
may be treatment failure rate (proportion of participants requir-
ing an intervention within 28 days of the treatment under test),
although this in itself is also open to confounding.
Recent research suggests that quantitative microbiological mea-
sures appear not to change prior to the onset of a pulmonary ex-
acerbation (Stressmann 2011); and do not change considerably
despite the administration of antibiotics (Stressmann 2012).With
person-to-person differences in the number and diversity of infect-
ing bacteria being considerable (Stressmann 2012) and an aware-
ness that healthy lungs are host to a microbiome of their own
(Blainey 2012), consideration of a more considered and person-
alised approach would appear to be of interest. With any effect
of antibiotics administered during exacerbations perhaps not act-
ing as originally expected, further understanding of the nature of
exacerbations and investigation of the bacterial-host interaction
further detailing the nature of their effect is also needed.
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The evolution of new agents targeting the specific molecular de-
fect is likely to change the ’natural history’ of CF, at least for
some people. Nevertheless a significant proportion of people with
CF do not adequately recover from their pulmonary exacerbation
and females in particular experience less favourable outcomes than
males. The significance of exacerbations for people with CF, and
so the importance of further work to refine the treatment of these
events, cannot be understated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agostini 1983
Methods Double-blind, RCT with multiple arms comparing 7 different IV antibiotics
Parallel design.
Duration: 10 - 15 days.
Single centre.
Country: Italy.
Participants People with CF with a pulmonary exacerbation with P. aeruginosa isolated in pure or
predominant culture.
Age range: 1 - 24 years.
178 treatment episodes for 111 participants experiencing an acute or subacute exacer-
bation with a pure or predominant culture of P. aeruginosa identified as susceptible to
the antibiotics under test in the trial
Interventions 10 - 15 days IV treatment with azlocillin (20 participants), piperacillin (22 participants),
cefoperazone (20participants), ceftazidime (27participants), cefsulodin (22participants)
, cefotaxime or moxalactam
Ureidopenicillins (azlocillin, piperacillin): 400 mg/kg/day in 3 doses
Cephalosporins (cefoperazone, ceftazidime, cefsulodin, cefotaxime, moxalactam): 200
mg/kg/day in 3 doses
All participants continued with standard therapy (physiotherapy,mucolytic aerosol, pan-
creatic enzyme therapy)
Outcomes A unique clinical score (for which lung function was a component), radiology, sputum
bacterial count, blood and urine studies and adverse events
Notes The study appears to be reported in 2 publications Agostini 1983 and Mastella 1983;
Mastella 1983 appears to report the full trial with Agostini 1983 reporting before the
end of the trial
Some cases randomly assigned to treatment before results of sputum culture known and
not all subsequently fulfilled inclusion criteria - these cases excluded from therapeutic
trial but included for evaluation of side effects
The data are presented in terms of the unvalidated clinical score. We shall seek to contact
the study authors for clarification and for study data to include in a meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly assigned, but no
method given.
Allocation concealment (selection bias) Unclear risk No detail given.
50Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Agostini 1983 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind but no further
detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind but no further
detail given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals were not described. From the
more complete analysis, data are presented
for 111 participants while 113 infections
were described as ’correctly assigned’ in re-
lation to in vitro susceptibility. Participants
are described as being removed from the
study if there was a failure in treatment after
7 days although this is not described. Some
participants were randomised before the re-
sults of susceptibility testing were available.
In some cases the results indicated that par-
ticipants did notmeet inclusion criteria and
sowere excluded (although remained in the
analysis of side effects)
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias High risk UoA issues - a higher number of infections
than participants recruited
Black 1990
Methods RCT.
Parallel design.
Duration: not stated.
Single centre.
Country: Northern Ireland.
Participants 16 participants with CF experiencing an acute respiratory exacerbation
Age: 11 to 27 years.
Intervention 1: 8 participants.
Intervention 2: 8 participants.
Interventions Intervention 1: oral ciprofloxacin alone over 4 exacerbations
Intervention 2: oral ciprofloxacin alternating with azlocillin and tobramycin over 4 ex-
acerbations
Outcomes Adverse events. Lung function data measured but not reported
Notes This study appears to be reported in a conference abstract and a discursive paper review
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Black 1990 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomly assigned’ but no
detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No detail given.
Selective reporting (reporting bias) High risk Lung function data were measured but not
reported.
Other bias Low risk No detail given.
Blumer 2005
Methods Investigator-blinded RCT.
Parallel design.
Duration: expected duration 14 days, follow up 2 - 4 weeks after discontinuation of
therapy
Multicentre (16 centres).
Country: USA.
Participants 121 participants with a recent (usually < 1 month) culture of P. aeruginosa or B. cepacia
complex recruited at a protocol-defined exacerbation.
102 participants with P. aeruginosa infection susceptible to meropenem and ceftazidime
recruited to randomised trial and stratified according to disease severity
19 participants with B. cepacia or ceftazidime-resistant P. aeruginosa recruited to open-
label study - the open label study is analysed separately
Age:
>
= 5 years of age.
Intervention group 1: 50 participants.
Gender: 25 male; 25 female.
Age: age 5 - 12 years (n = 12), age >12 - 16 years (n = 13), age > 16 to < 65 years (n =
25)
Disease severity: FEV1 >70 % predicted (n = 11); FEV1 40% - 69% predicted (n = 21);
FEV1 < 40 % predicted (n = 18).
Intervention group 2: 52 participants.
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Blumer 2005 (Continued)
Gender: 28 male, 24 female.
Age: age 5 - 12 years (n = 9), age > 12 - 16 years (n = 11), age > 16 to < 65 years (n = 32)
Disease severity: FEV1 > 70 % predicted (n = 11); FEV1 40% - 69% predicted (n = 20)
; FEV1 < 40 % predicted (n = 21).
Interventions Intervention1: IVmeropenem40mg/kgup to amaximumdose of 2 g and IV tobramcyin
(given for a mean of 13.5 days)
Intervention 2: IV ceftazidime 50mg/kg up to amaximumdose of 2 g and IV tobramycin
(given for a mean of 14.1 days)
Tobramycin dose adjusted to give a peak serum concentration of
>
= 8 µg/mL and trough
concentration of < 2 µg/mL
Each infusion given over a 30-minute period.
Standard physiotherapy and other supportive therapy continued
Outcomes Lung function (FEV1, FVC, FEV1/FVC ratio, peak expiratory flow, forced expiratory
flow, FEV1 % predicted, FVC % predicted), acute change score, time to next exacerba-
tion, microbiology, mortality and adverse effects
Notes Sample size calculated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Investigator” blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The report indicates that the ’investigator’
was blinded but that this did not include
assessing all the outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk Some ’evaluable’ data for lung function and
microbiology data are missing. 2 ’clinically
evaluable’ participants (1 from each group)
withdrew
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias Low risk None identified.
53Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bosso 1988
Methods RCT.
Parallel design.
Duration: last measurement 7 - 14 days after completion of treatment
Single centre.
Country: USA.
Participants 30 participants with CF experiencing protocol-defined pulmonary exacerbation
Age: > 6 years.
Intervention 1: 15 participants; mean age 14.1 years; 9 males, 6 females
Intervention 2: 15 participants; mean age 14.7 years; 6 males, 9 females
Interventions Intervention 1: IV aztreonam (50 mg/kg 4x daily) for a mean of 17.2 days
Intervention 2: IV azlocillin and IV tobramycin (azlocillin - 350 mg/kg/day in 4 divided
doses and tobramycin to reach target serum concentration) for a mean of 14.8 days
Outcomes Lung function (FEV1 / FVC), microbiology and adverse effects.
Notes No sample size calculation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ’randomly assigned’ but no
detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk None identified.
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias Low risk None identified.
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Bosso 1989
Methods Open-label RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: USA.
Participants 25 adults with CF and a protocol-defined pulmonary exacerbation
Intervention 1: 24 participants; mean (SD) age 22.9 (7.37) years
Intervention 2: 24 participants; mean (SD) age 23.1 (4.5) years
Interventions Intervention 1: oral ciprofloxacin (750 mg 2x daily).
Intervention 2: IV tobramycin (to achieve peak 8 - 10 µg/ml; trough < 2 µg/ml) and IV
azlocillin (75 mg/kg 4x a day)
Outcomes Lung function (FEV1, FVC), microbiology, adverse effects.
Notes The 1987 report details findings for the first 20 participants (of whom 7 withdrew). The
1989 report details findings for 25 participants of whom 24 were evaluable. Not possible
to determine if the 7 withdrawals are included in the later report or if the cohort is a
completely different recruitment
We shall seek to contact the authors for IPD to determine the ITT analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly assigned’.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label.
Incomplete outcome data (attrition bias)
All outcomes
High risk 5withdrawals are discussed andwhile a sep-
arate analysis is included to compare those
who completed the protocol with those that
did not, the withdrawals were not included
in the final analysis
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias Low risk None identified.
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BTS 1985
Methods Open RCT.
Parallel design.
Duration: a minimum of 7 days, follow up for 3 months.
Multicentre study.
Country: UK.
Participants 92 participants with CF and an acute exacerbation fromwhose sputum P. aeruginosa had
been isolated on 2 occasions in the previous 6 months.
Aged: > 5 years.
Intervention 1: 42 participants; mean age (range) - 15.5 (6 - 28) years; 56% females
Intervention 2: 50 participants; mean age (range) - 16.2 (5 - 34) years; 52% females
Interventions Intervention 1: IV carbenicillin 5 g 6-hourly (for under 14 years of age 10 mg/kg 3x
daily) and IV gentamicin 80 mg 3x daily (for under 14 years of age 2 mg/kg 3x daily)
Intervention 2: IV ceftazidime 2g 3x daily (for under 14 years of age 40 mg/kg 3x daily)
Outcomes Lung function (PEFR), nutritional status (weight), adverse effects (including plasma
urea, electrolytes and liver function)
Notes We shall contact the authors for data for inclusion in a meta-analysis
Unit of analysis issues - 9 participants had 2 courses.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but details not
given.
Allocation concealment (selection bias) Low risk Sequential envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open trial.
Incomplete outcome data (attrition bias)
All outcomes
High risk 12 not evaluated for a number of reasons
including lost records
Selective reporting (reporting bias) Unclear risk No detail.
Other bias High risk UoA issues - 9 participants had 2 courses.
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Caplan 1984
Methods Mixed report with randomised and non-randomised participants
Parallel design.
Duration: at least 3 days (mean 11.4 days).
Single centre.
Country: USA.
Participants 29 participants with CF and with P. aeruginosa as the ’significant infecting organism’
randomised.
Age: range 12 - 30 years.
Intervention 1: 14 participants; 8 females.
Intervention 2: 15 participants; 8 females.
Interventions Intervention 1: cefsulodin 100 mg/kg per day.
Intervention 2: tobramycin 10 mg/kg day (14 participants) or ticarcillin (300 mg/kg/
day) (1 participant)
Outcomes Adverse effects and microbiology described. Lung function was measured but not re-
ported
Notes Randomised portion of the study reported separately, although there were 2 deaths - of
those who received cefsulodin, although it is not clear if they were in the randomised
portion of the study. The study is described as ongoing, although we could find no
complete report
We shall seek to contact the authors for IPD to quantify the change in lung function
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no method
described.
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals described.
Selective reporting (reporting bias) High risk Lung function was measured but not re-
ported.
Other bias Unclear risk None identified.
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Church 1997
Methods Double-blind RCT.
Parallel design.
Duration: minimum of 10 days.
Multicentre study.
Country: USA.
Participants 130 participants with CF enrolled and a protocol-defined exacerbation and P. aeruginosa
infection.
Age: range 5 - 17 years.
Intervention 1: 41 participants; mean (SD) age 11.7 (3.1); 42%males; 18/41 had FEV1<
40%.
Intervention 2: 43 participants; mean (SD) age 11.6 (3.3); 56%males; 17/43 had FEV1<
40%.
Interventions Intervention 1: IV ciprofloxacin (10 mg/kg 3x daily) for 7 days followed by oral cipro-
floxacin 20 mg/kg 2x daily for a minimum 3 days
Intervention 2: IV ceftazidime (50 mg/kg 3x daily) and IV tobramycin (3 mg/kg 3x
daily) for a minimum 10 days
Outcomes Lung function (FEV1, FVC) and adverse effects.
Notes 130 recruited, 46 were not evaluable of whom only 25 are accounted for
No standard deviations are given for the change in lung function over time and the
durations of treatment in the two groups are not reported. We shall seek to contact the
authors for IPD to quantify the change in lung function
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomly assigned’ but no detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind but no detail.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind but no descrip-
tion on outcome assessment, other than the
estimation of antimicrobial sensitivity was
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 46participantswere not evaluable ofwhom
25 are accounted for
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
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Church 1997 (Continued)
Other bias Low risk None identified.
Conway 1985
Methods RCT.
Parallel design.
Single centre.
Country: UK.
Participants 17 participants with CF and chronic P. aeruginosa and a protocol-defined exacerbation
for whom bacterial sensitivity to the antibiotics allocated was confirmed (contributed 30
courses of treatment)
Intervention 1: 15 participants, 12 females, 3 males.
Intervention 2: 15 participants, 11 females, 4 males.
Interventions Intervention 1: (median dose) IV netilmicin (10 mg/kg/day) and IV ticarcillin (468 mg/
kg/day)
Intervention 2: (median dose) IV tobramycin (9.2 mg/kg/day) and IV ticarcillin (586
mg/kg/day)
Anti-staphylococcal therapy also given.
Outcomes Unvalidated clinical score, lung function (PEFR, FEV1, FVC), weight.
Notes UoA issues addressed narratively with a second analysis with the participant as the UoA,
rather than the treatment episode
We shall seek to contact the authors for IPD to quantify the change in lung function to
include in any meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly assigned but no de-
tail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Only radiographer was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on withdrawals given.
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Conway 1985 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias High risk UoA issues - 17 participants contributed to
30 treatment courses
Conway 1997
Methods Single-blind RCT.
Parallel design.
Duration: 12 days.
Single centre.
Country: UK.
Participants 53 participants with CF and chronic P. aeruginosa experiencing a protocol-defined exac-
erbation.
Intervention 1: 36 participants; mean (SD) age 21.7 (4.2) years; 17 females, 19 males;
mean (SD) FEV1 % predicted 43.3 (16.6).
Intervention 2: 35 participants; mean (SD) age 21.2 (4.25) years; 12 females, 23 males;
mean (SD) FEV1 % predicted 45.8 (21.8).
Interventions Intervention 1: IV colistin (2 MU 3x daily).
Intervention 2: IV colistin (2 MU 3x daily) and a second anti-pseudomonal antibiotic
Outcomes Lung function (FEV1, FVC), weight, mortality and adverse events.
Notes UoA issues - 18 participants were enrolled twice.
We shall seek to contact the authors for IPD to reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single blind (outcome assessor).
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Laboratory and radiology were blinded
(unclear if physiological outcome assessors
were blinded)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9 withdrawals described and analysed as
ITT.
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Conway 1997 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - 18 participants enrolled 2x.
Cooper 1985
Methods RCT.
Parallel design.
Duration: unspecified.
Single centre.
Country: Canada.
Participants 18 participants with CF and an exacerbation and P. aeruginosa infection.
Intervention 1: 10 participants.
Intervention 2: 8 participants.
Interventions Intervention 1: IV tobramycin and IV ticarcillin (dose and regimen unstated)
Intervention 2: inhaled tobramycin and inhaled carbenicillin (dose and regimen un-
stated)
Outcomes Lung function (FEV1, FVC % predicted).
Notes We shall seek to contact the authors for IPD to include in any meta-analysis. Currently
SDs for the mean changes observed are not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly allocated but no de-
tail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants in each group needed addi-
tional antibiotics. Unclear if this was anal-
ysed as ITT
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
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Cooper 1985 (Continued)
Other bias Low risk None identified.
Costantini 1982
Methods RCT.
Parallel design.
Duration: mean duration of 15 days.
Single centre.
Country: Italy.
Participants 19 participants with CF colonised with P. aeruginosa experiencing an exacerbation over
28 exacerbation episodes.
Intervention 1: 7 participants.
Intervention 2: 10 participants.
Invtervention 3: 11 participants.
Interventions Intervention 1: IV carbenicillin 675 mg/kg/day (mean dosage)
Intervention 2: IV sisomicin 10.5 mg/kg/day (mean dosage).
Invtervention3: IV carbenicillin 590mg/kg/dayANDIV sisomicin 10mg/kg/day (mean
dosage)
Outcomes Unvalidated clinical score, microbiology and adverse effects
Notes We shall seek to contact the authors for IPD to reconcile the UoA issues and quantify
unpublished data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals described.
Selective reporting (reporting bias) Unclear risk Insufficient information.
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Costantini 1982 (Continued)
Other bias High risk UoA issues - 19 participants contributed
28 treatment episodes
De Boeck 1989
Methods RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: Belgium.
Participants 21 participants with CF and a protocol-defined pulmonary exacerbation, chronically
infected with P. aeruginosa that was sensitive to piperacillin, tobramycin and ceftazidime
Intervention 1: 10 participants.
Intervention 2: 11 participants.
Interventions Intervention 1: IV ceftazidime 50 mg/kg 3x daily.
Intervention 2: IV piperacillin 75 mg/kg 4x daily and IV tobramycin 10 mg/kg/day in
3 doses
Outcomes Lung function (FEV1), time to next exacerbation, weight, mortality.
Notes We shall seek to contact the authors for IPD to include in any meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation stated but not described.
Allocation concealment (selection bias) Unclear risk No information given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and clinicians were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Lung function undertaken by a technician
blinded to regimen.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals.
Selective reporting (reporting bias) Unclear risk None identified.
Other bias Low risk None identified.
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De Boeck 1999
Methods RCT of those with exacerbation and those receiving elective treatment
Parallel design.
Duration: 14 days.
Single centre.
Country: Belgium.
Participants 40 participants with CF and chronic P. aeruginosa infection (sensitive to agent under
test), 46 treatments were given for treatment of an exacerbation; 29 courses for elective
or suppressive treatment
Mean (SD) age 14.8 (4.4) years.
Interventions Intervention 1: IV meropenem 150 mg/kg/day.
Intervention 2: IV ceftazidime 200 mg/kg/day and tobramycin 10 mg/kg/day
Outcomes Lung function, weight.
Notes We shall seek to contact the authors for IPD of those experiencing an exacerbation to
reconcile the UoA issues (multiple enrolment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but method not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawals not described.
Selective reporting (reporting bias) Unclear risk Narrative data in the abstract.
Other bias High risk UoA issues - 40 participants contribute 46
treatment episodes
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Elborn 1992
Methods RCT.
Parallel design.
Duration: 2 weeks.
Single centre.
Country: UK.
Participants 24 participants with CF and chronic P. aeruginosa infection experiencing exacerbations.
Mean (range) age 20 (14 - 48) years. 12 male, 12 female.
Interventions Intervention 1: IV ceftazidime 2 g 3x daily.
Intervention 2: IV aztreonam 2 g 3x daily.
Outcomes Lung function (FEV1), ’symptom scores’, sputum weight, inflammatory markers (CRP,
neutrophil elastase, TNF-α, α-1 antitrypsin complex C)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Desccribed as randomised but no method
detailed.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals described.
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Low risk No other bias identified.
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Gold 1985
Methods RCT.
Parallel design.
Duration: 10 - 14 days.
Single centre.
Country: Canada.
Participants 30 participants with CF and P. aeruginosa infection present at the previous clinic visit,
experiencing an acute respiratory exacerbation. Participants deemed to be experiencing
a severe exacerbation (protocol defined) were excluded
Intervention 1: 17 participants; mean (SE) age 18.9 (1.1) years; 15 males, 2 females
Intervention 2: 13 participants; mean (SE) age 17.8 (0.8) years; 9 males, 4 females
Interventions Intervention 1: IV ceftazidime 200 mg/kg/day in 4 doses.
Intevention 2: IV ticarcillin 300 mg/kg/day in 4 doses and IV tobramycin 10 mg/kg/
day in 3 doses
Outcomes Lung function (FEV1, FEF25−75%), weight, microbiology, adverse effects.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a table of random num-
bers used.
Allocation concealment (selection bias) Unclear risk No detail.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals.
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Low risk No other bias identified.
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Gold 1987
Methods Double-blind placebo-controlled RCT.
Parallel design.
Duration: 14 days treatment with 6 - 24 months follow up.
Single centre.
Country: Canada.
Participants 26 participants experiencing a protocol-defined pulmonary exacerbation. Participants
were excluded if they were considered to be experiencing a severe exacerbation (protocol-
defined)
Intervention 1: 16 participants; mean (95% CI) age 17.9 (17 - 18.8) years; 4 males, 12
females
Intervention 2: 15 participants; mean (95% CI) age 18.5 (17.3 - 19.7) years; 9 males, 6
females
Interventions Intervention 1: IV ceftazidime 200 mg/kg/day in 4 doses.
Intervention 2: IV placebo (colour-matched vitamin B complex)
Outcomes Lung function (FEV1 and VC), weight, microbiology, unvalidated clinical and symptom
scores
Notes UoA issues - 5 participants were treated 2x. 3 participants in placebo group wished to
withdraw as the lack of discolouration of their urine indicated to them that they were
not in the intervention group
We shall seek to contact the authors for IPD to reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Colour-matched placebo, although it is
known that ceftazidime discolours the
urine. 3 participants noted an absence of
discolouration and wished to withdraw
from the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor was blinded to alloca-
tion.
Incomplete outcome data (attrition bias)
All outcomes
High risk The 3 participants who withdrew did not
contribute to the analysis
Selective reporting (reporting bias) Unclear risk Insufficient information.
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Gold 1987 (Continued)
Other bias High risk UoA issues - 5 participants treated 2x.
Hodson 1987
Methods RCT.
Parallel design.
Duration: 10 days treatment with 6 weeks follow up.
Single centre.
Country: UK.
Participants 40 participants with CF and chronic P. aeruginosa infection (over 6 months) admitted
to hospital experiencing a pulmonary exacerbation
Mean (range) age 23 (18 - 35) years.
Intervention 1: 20 participants.
Intervention 2: 20 participants.
Interventions Intervention 1: oral ciprofloxacin 500 mg 3x daily.
Intervention 2: IV azlocillin 5 g 3x daily and IV gentamicin 80 mg 3x daily
Outcomes Lung function (peak flow, FEV1, FVC), mortality, adverse effects, microbiology.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described a random allocation but no de-
tail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Lung function was tested by an ’investiga-
tor who was not involved in the study’ al-
though it is unclear if this assessor was truly
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data for all participants were available at
10 days, but only data for 15 participants
in each group were available at 6 weeks
Selective reporting (reporting bias) Unclear risk Insufficient information.
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Hodson 1987 (Continued)
Other bias Low risk No additional bias noted.
Huang 1983
Methods Double-blind RCT.
Parallel design.
Duration: 2 weeks.
Single centre.
Country: USA.
Participants 29 participants with CF experiencing a protocol-defined exacerbation with sputum bac-
teria that were sensitive to both azlocillin and carbenicillin
Intervention 1: 12 participants; median (range) age 12.25 (6.5 - 24.5) years; 4 males, 8
females
Intervention 2: 14 participants; median (range) age 12.5 (5.75 - 21) years; 7 males, 7
females
Interventions Intervention 1: IV azlocillin 250 mg/kg/day in 5 doses.
Intervention 2: IV carbenicillin 500 mg/kg/day in 5 doses.
Outcomes Lung function (unstated), microbiology, adverse effects and a scoring system
Notes 3participantswerewithdrawn from the study (2 had rashes and 1 developed cholecystitis)
and did not contribute data to the analysis
The results are presented in terms of the clinical score and so we shall seek to contact
the authors for IPD to contribute to a meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code developed by statisti-
cian and kept in pharmacy
Allocation concealment (selection bias) Unclear risk No detail other than “kept in pharmacy”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ’double-blind’ but no detail
given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as ’double-blind’ but no detail
given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawn participants did not contribute
to analysis.
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Huang 1983 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Low risk No further biases identified.
Hyatt 1981
Methods Double-blind RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: USA.
Participants 15 participants with CF experiencing an acute exacerbation, each with P. aeruginosa
isolated from 3 out of 4 most recent samples.
Age: range 6 - 21 years; gender split not detailed.
Intervention 1: 9 participants.
Intervention 2: 15 participants.
Interventions Intervention 1: IV oxacillin 35 mg/kg 6x daily and IV ’placebo fluids’ 6x daily
Intervention 2: IV oxacillin 35 mg/kg 6x daily and IV carbenicillin 65 mg/kg 6x daily
and IV sisomicin 70 mg/m2 6x daily.
Outcomes Lung function (FEV1, FVC, RV), microbiology, adverse effects, symptom score, treat-
ment ’failure’ (early withdrawal due to poor response, or additional treatment required
at the end of the 14-day period)
Notes UoA issues - 9 participants contributed more than once to the study. The unequal
assignment to the 2 groups (9 to the control group and 15 to the treatment group
(intervention 2) occurred through chance alone
Oxacillin masked the odour of carbenicillin in the participants’ urine
We shall seek to contact the authors for IPD to reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a table of random
numbers.
Allocation concealment (selection bias) Low risk Antibiotics and placebo were prepared in
pharmacy and delivered in coded bottles.
Code was not broken in case of ’treatment
failure’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as ’double-blind’. Antibiotics
and placebo were prepared in pharmacy
and delivered in coded bottles. Code was
not broken in case of ’treatment failure’.
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Hyatt 1981 (Continued)
Sham serum levels of sisomicin given by
(unblinded) pharmacists
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as ’double-blind’ with parents,
participants and clinicians blinded as above
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the case that participants were removed
from the study due to “early failure” (con-
trol n = 3 out of 9; treatment n = 2 out of
15) the data from the last day of study par-
ticipation contributed to the data analysis
Selective reporting (reporting bias) Unclear risk Insufficient data.
Other bias High risk UoA issues - 9 participants recruited more
than 1x.
Knowles 1988
Methods RCT.
Parallel design.
Duration: 12 - 14 days, then 4-week post-hospitalisation visit
Country: USA.
Participants 19 CF participants with an acute exacerbation.
Intervention 1: 10 participants.
Intervention 2: 9 participants.
Analysis of baseline variables showed that Group 2 were “sicker”
Interventions Intervention 1: IV piperacillin and tobramycin.
Intervention 2: IV piperacillin and tobramycin plus aerosolised piperacillin and to-
bramycin
Outcomes Chest radiograph score, clinical score, weight, total WBC, absolute band count, pul-
monary function tests (FVC, FEV1, PEFR), time in weeks to additional antibiotic use,
time in months to next hospitalisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No method described.
71Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Knowles 1988 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open study.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information.
Selective reporting (reporting bias) High risk Time to next hospitalisation was recorded
but not reported.
Other bias Low risk None identified.
Macfarlane 1985
Methods Double-blind placebo-controlled RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: Australia.
Participants 19 participants aged over 8 years with CF with P. aeruginosa in sputum admitted to
hospital for worsening respiratory status
Intervention 1: 4 participants; mean (SD) age 15.3 (3) years
Intervention 2: 5 participants; mean (SD) age 12.5 ( 2.9) years
Intervention 3: 4 participants; mean (SD) age 13.7 ( 2.6) years
Intervention 4: 5 participants; mean (SD) age 15.6 (3.4) years
Gender split not detailed.
Interventions Intervention 1: IV piperacillin 50 mg/kg 4-hourly.
Intervention 2: IV placebo 5% dextrose 4-hourly.
Intervention 3: IV piperacillin 100 mg/kg 8-hourly.
Intervention 4: IV placebo 5% dextrose 8-hourly.
All participants received IV tobramycin 2.5 mg/kg 3x daily, oral flucloxacillin 25 mg/
kg/day in 4 doses and oral probenecid (suggested to increase antibiotic concentrations)
250 - 500 mg 3x daily
Outcomes Lung function (FEV1, VC, RV, TLC, FEF25−75%), weight, symptom and clinical score,
mortality, microbiology
Notes UoA issues - 1 participants received 2 courses.
We shall seek to contact the authors for IPD to reconcile the UoA issues and for data to
contribute to a meta-analysis
Risk of bias
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Macfarlane 1985 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly assigned but no
method given.
Allocation concealment (selection bias) Unclear risk No method described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind. Identities of in-
fusions known only to pharmacy personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind.
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 participants withdrew and did not con-
tribute data to the analysis
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - 1 participant received 2 treat-
ment courses.
Master 2001
Methods Double-blind RCT.
Parallel design.
Duration: at least 10 days.
Single centre.
Country: Australia.
Participants 51 participants with CF experiencing a protocol-defined exacerbation with P. aeruginosa
isolated from sputum. Participants with an FVC lower than 40%predictedwere excluded
Intervention 1: 21 participants; mean (SD) age 16 (7) years.
Intervention 2: 23 participants; mean (SD) age 15 (5) years.
Interventions Intervention 1: IV ceftazidime 50 mg/kg/dose 3x daily and IV tobramycin 3 mg/kg/
dose 3x daily
Intervention 2: IV tobramycin 9 mg/kg/day 1x daily.
Outcomes Lung function (FEV1, FVC, FEF25−75%), radiology, microbiology, adverse effects, time
to next exacerbation
Notes UoA issues - each participant contributed on average 3 episodes
Study was suspended for 3 months after 1 participant committed suicide, data from this
period were not included
We shall seek to contact the study authors for individual study data
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Master 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, stratified for age
and disease progression, but nomethod de-
tailed
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind with medical
and nursing staff and participants blinded
with identical syringes and placebos
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals were described and those par-
ticipants who completed 10 days treatment
but excluded for other reasons were in-
cluded in an ITT analysis. The ITT anal-
ysis is described as not changing the effect
of the short-term analysis, but no data pro-
vided
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - each participant contributed
multiple treatment episodes
McCarty 1988
Methods Open-label RCT.
Parallel design.
Duration: at least 10 days.
Single centre.
Country: USA.
Participants 17 children with CF admitted for treatment of pulmonary exacerbations
Age: range 2 - 12 years.
Gender split not detailed.
Intervention 1: 8 participants.
Intervention 2: 9 participants.
Interventions Intervention 1: IV piperacillin 600 mg/kg/day (regimen not detailed)
Intervention2: IVpiperacillin 600mg/kg/day and tobramycin 8 - 10mg/kg/day(regimen
not detailed)
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McCarty 1988 (Continued)
Outcomes Lung function (PEFR, FEV1, FVC), weight, clinical score, microbiology, mortality,
adverse effects
Notes UoA issues - 3 participants were included 2x. No data provided for lung function and
nutritional status
We shall seek to contact the study authors for IPD to include in a meta-analysis and
reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly assigned but no de-
tail given.
Allocation concealment (selection bias) Low risk Sequentially numbered envelopes were
used, although it is not clear if these were
opaque and sealed. On balance, considered
low risk
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals.
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - 3 participants were included
twice.
McLaughlin 1983
Methods Part-placebo-controlled double-blind RCT.
Parallel design.
Duration: 10 days.
Dual centre study.
Country: USA.
Participants 60 participants with CF experiencing an exacerbation requiring hospital admission
Age: mean (SD) 21 (5) years; range 11 - 30 years.
Gender split not detailed.
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McLaughlin 1983 (Continued)
Intervention 1: 17 participants.
Intervention 2: 18 participants.
Intervention 3: 16 participants.
Interventions Intervention 1: IV ticarcillin 300 mg/kg/day in 6 doses and IV tobramycin 6 mg/kg/day
in 3 doses
Intervention 2: IV azlocillin 300 mg/kg/day in 6 doses and IV tobramycin 6 mg/kg/day
in 3 doses
Intervention 3: IV azlocillin 300 mg/kg/day in 6 doses and placebo 0.85% saline in 3
doses
Outcomes Lung function (FEV1, VC, maximal mid-expiratory flow rate, RV), microbiology, an-
tibiotic susceptibility, adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned by pharmacist, but no
detail on method.
Allocation concealment (selection bias) Low risk Pharmacist used consecutively numbered
sealed envelopes, but it is not clear if they
were opaque, on balance considered low
risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither participants nor physicians know
which regimen was prescribed”, but no
other detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double blind, but no other
detail given.
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 participants withdrew, or data were not
available for analysis. 3 participants ex-
cluded as they had incomplete lung func-
tion or bacteriology data available
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Low risk No other bias identified.
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Padoan 1987
Methods RCT.
Parallel design.
Duration: average of 14 days.
Single centre.
Country: Italy.
Participants 30 participants with CF and moderate to severe lung disease with chronic P. aeruginosa
infection experiencing an acute exacerbation.
Intervention 1: 20 participants; mean (SD) age 12 years 2 months (5 years); 9 males, 11
females
Intervention 2: 20 participants; mean (SD) age 11 years (3 years); 5 males, 15 females
Intervention 3: 20 participants; mean (SD) age 10 years 3 months (4 years 11 months);
4 males 16 females
Interventions Intervention 1: IV ceftazidime 50 mg/kg 3x daily.
Intervention 2: IV ceftazidime 50 mg/kg 3x daily and IV sisomicin 3 mg/kg 3x daily
Intervention 3: IV piperacillin 100 mg/kg 3x daily and IV sisomicin 3 mg/kg 3x daily
Outcomes Clinical score, microbiology, adverse effects.
Notes UoA issues - 30 participants contributed 60 treatment episodes
As the data was collated and presented in the form of a clinical score, we shall seek to
contact the study authors for IPD to include in a meta-analysis and reconcile the UoA
issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly assigned but no
method given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as a ’blind study’ but little detail
given other than participants likely to be
blinded as given a saline infusion given in-
stead of active drug in monotherapy group
(although no detail on procedure/prepara-
tion)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as a ’blind study’ but no detail
given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported.
Selective reporting (reporting bias) Unclear risk Insufficient information.
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Padoan 1987 (Continued)
Other bias High risk UoA issues - 30 participants contributed
60 treatment episodes
Penketh 1983
Methods Single-blind RCT.
Parallel design.
Duration: 10 days.
Single centre.
Country: UK.
Participants 16 adults with CF and chronic P. aeruginosa infection admitted with deteriorating lung
function and acute respiratory symptoms
Intervention 1: 8 participants; age range 16 - 26 years; 5 males, 3 females
Intervention 2: 8 participants; age range 21 - 33 years; 4 males, 4 females
Interventions Intervention 1: IV ticarcillin 5 g 6-hourly and IV gentamicin 8-hourly (dose adjusted to
achieve peak serum level 8 - 10 µg/ml)
Intervention 2: IV carbenicillin 5 g 6-hourly and IV gentamicin 8-hourly (dose adjusted
to achieve peak serum level 8 - 10 µg/ml)
Outcomes Lung function (PEFR, FEV1, FVC), time to next exacerbation and adverse effects.
Notes Means only (no SD) detailed for lung function and time to next exacerbation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Only participants blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded healthcare personnel.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals described.
Selective reporting (reporting bias) Unclear risk Insufficient information.
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Penketh 1983 (Continued)
Other bias Low risk None identified.
Penketh 1984
Methods Single blind RCT.
Parallel design.
Duration: 10 days.
Single centre.
Country: UK.
Participants 20 adults with CF and chronic P. aeruginosa infection admitted with a protocol-defined
exacerbation. People with severe disease (FEV1 < 20% predicted) were excluded.
Intervention 1: 10 participants; age range 18 - 25 years; 6 males, 4 females
Intervention 2: 10 participants; age range 17 - 29 years; 9 males, 1 female
Interventions Intervention 1: IV azlocillin 5 g 3x daily and IV gentamicin (dose adjusted to achieve
peak serum level 8 - 10 µg/ml)
Intervention 2: IV carbenicillin 5 g 4-hourly and IV gentamicin (dose adjusted to achieve
peak serum level 8 - 10 µg/ml)
Outcomes Lung function (PEFR, FEV1, FVC), time to next exacerbation, mortality and adverse
effects
Notes Participants identified as having other pathogens in sputum were given ’appropriate oral
antibiotics’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly allocated but no detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ’Single-blind’ study.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals described.
Selective reporting (reporting bias) Unclear risk Insufficient information.
79Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Penketh 1984 (Continued)
Other bias Low risk None identified.
Regelmann 1990
Methods Double-blind placebo-controlled RCT.
Parallel study.
Duration: 14 days.
Single centre.
Country: USA.
Participants 15 participants with CF and chronic P. aeruginosa infection who had experienced a
deterioration in FEV1 greater than 10% over previous 1 - 6 months.
Intervention 1; 8 participants; mean (SD) age 21 (6.5) years; 6 males, 2 females
Intervention 2: 5 participants; mean (SD) age 22 (7.2) years; 3 males, 2 females
Interventions Lead-in period of 4 days consisting of chest physiotherapy and bronchodilators then
those that did not deteriorate further were randomised to receive 1 of following
Intervention 1; IV tobramycin 3 mg 1x daily and IV ticarcillin 70 mg/kg with dose
frequency adjusted to achieve target range
Intervention 2: IV placebo (dextrose water).
Outcomes Lung function (FEV1, FVC, FEF25−75%), weight, adverse effects.
Notes An improvement in weight and lung function was observed in the lead-in period before
antibiotic therapy was commenced. It is uncertain whether this improvement reduced
the measured change in the placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by table of random numbers.
Allocation concealment (selection bias) Unclear risk No detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double blind. Little infor-
mation given, sham dose adjustment of
placebo was given a well as treatment
groups
One investigator not involved in clinical
care was unblinded and responsible for dos-
ing and allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double blind but little detail
provided.
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Regelmann 1990 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 participant withdrew from the placebo
armonday 3 and did not contribute data. 4
participants contribute lung function data
for the placebo group compared to 8 par-
ticipants in the antibiotic group
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - 1 participant re-entered the
study after a 2-year gap
Richard 1997
Methods Open-label RCT.
Parallel design.
Duration: 14 days.
Multicentre study.
Countries: France, Germany, Greece, Hungary, Israel, Italy, Portugal, South Africa and
Switzerland
Participants 108 children with CF and P. aeruginosa infection and experiencing a protocol-defined
pulmonary exacerbation
Intervention 1: oral ciprofloxacin - mean age 10.2 years; 32 males, 23 females
Intervention 2: IV ceftazidime and IV tobramycin - mean age 11.0 years; 27 males, 26
females
Interventions Intervention 1: oral ciprofloxacin 15 mg/kg 2x daily.
Intervention 2: IV ceftazidime 50 mg/kg 3x daily and IV tobramycin 3 mg/kg 3x daily
Outcomes Lung function (FEV1, FVC), time to next exacerbation, adverse effects, microbiology,
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
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Richard 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk The efficacy and safety analysis were de-
scribed as analysed on an ITT basis
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Unclear risk An author on the paper is affiliated to
Pharma Research Center, Bayer AG. Bayer
produced ciprofloxacin
Salh 1992
Methods Double-blind RCT.
Parallel design.
Duration: 2 weeks.
Single centre.
Country: UK.
Participants 22 participants with CF and P. aeruginosa sensitive to the study drugs who were admitted
to hospital due to an infective exacerbation
Age: 16 - 32 years.
Gender split: aztreonam - 6 females, 8 males; ceftazidime - 4 females, 8 males
Interventions Intervention 1; IV aztreonam 8 g/day in 4 doses.
Intervention 2: IV ceftazidime 8 g/day in 4 doses.
Outcomes Lung function (FEV1), symptom score, weight, adverse effects.
Notes UoA issues - 4 participants received both drugs on separate occasions
We shall seek to contact the study authors for IPD to include in a meta-analysis and
reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised in pharmacy using ’simple
random allocation’.
Allocation concealment (selection bias) Low risk Sealed opaque envelopes but unclear
whether sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind infusions pre-
pared in pharmacy and labelled with trial
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Salh 1992 (Continued)
number
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear, but as the physicians and partici-
pants were blinded it is likely the outcome
assessors were also blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4withdrew (3 of whomwere treatment fail-
ures), it is unclear if these contributed to
the analysis
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias High risk UoA issues - 4 participants contribute mul-
tiple treatment episodes
Schaad 1986
Methods RCT.
Parallel design.
Duration: 2 weeks.
Single centre.
Country: Switzerland.
Participants 29 participants with CF who were admitted for treatment of an exacerbation and had P.
aeruginosa isolated on admission. Participants with severe disease were excluded
Intervention 1: 21 participants; mean (range) age 14.5 (4 - 22) years; 11 males, 10
females
Intervention 2: 21 participants; mean (range) age 16.5 (5 - 23) years; 9 males, 12 females
Interventions Intervention 1: IV netilmicin 11 mg/kg/day in 3 doses and IV azlocillin 500 mg/kg/day
in 4 doses
Intervention 2: IV netilmicin 11 mg/kg/day in 3 doses and IV ticarcillin 500 mg/kg/day
in 4 doses
Outcomes Lung function (VC, RV), nutritional status (relative underweight (%)), adverse effects
Notes 29 participants received 42 courses of therapy, although only the 1st treatment course
was used for analysis, thus negating a UoA issue
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random allocation, but no detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
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Schaad 1986 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Due to in vitro resistance pattern, 2 partic-
ipants changed from azlocillin to ticarcillin
and 2 participants changed from ticarcillin
to azlocillin. It is unclear if these data fea-
ture in the final analysis
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias Low risk UoA issues accommodated in analysis -
only the 1st treatment course was used for
analysis
Schaad 1987
Methods RCT.
Parallel design.
Duration: 15 days.
Single centre.
Country: Switzerland.
Participants 62 participants with CF admitted with an acute pulmonary exacerbation who had P.
aeruginosa isolated on admission. Those who had been admitted to hospital in the recent
6 months were excluded
Age: range 3 - 24 years.
Gender split: not detailed.
Intervention 1: 24 participants.
Intervention 2: 30 participants.
Interventions Intervention 1: IV ceftazidime 250 mg/kg/day in 4 doses and IV amikacin 33 mg/kg/
day in 3 doses
Intervention 2: IV ceftazidime 250 mg/kg/day in 4 doses and IV amikacin 33 mg/kg/
day in 3 doses and nebulised amikacin 100 mg 2x daily
Outcomes Lung function (VC), nutritional status (degree of underweight (%)), adverse effects
Notes UoA issues - 62 participants received 87 courses of therapy.
We shall seek to contact the study authors for IPD to include in a meta-analysis and
reconcile the UoA issues
Risk of bias
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Schaad 1987 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomly allocated but no de-
tail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information on blinding given.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical evaluator blinded to treatment al-
location.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals.
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias High risk UoA issues - 13 participants enrolled 2x
and 6 participants enrolled 3x
Schaad 1989
Methods RCT.
Parallel design.
Duration: 2 weeks IV treatment, with oral treatment extended for a further 4 weeks in
1 group
Single centre.
Country: Switzerland.
Participants 42 participants with CF admitted with a protocol-defined pulmonary exacerbation and
P. aeruginosa isolated at admission. Those who had been admitted to hospital in previous
4 months were excluded
Age: mean (SD) 15.4 (6) years (range 2.3 - 25.4 years).
Gender split not detailed.
Intervention 1: 28 participants.
Intervention 2: 28 participants.
Interventions Intervention 1: IV aztreonam 300 mg/kg/day in 4 doses and IV amikacin 36 mg/kg/day
in 3 doses
Intervention 2: IV ceftazidime 300 mg/kg/day in 4 doses and IV amikacin 36 mg/kg/
day in 3 doses for 2 weeks followed by oral ciprofloxacin 30 mg/kg/day for 4 weeks
Outcomes Lung function (FEV1, VC), nutritional status (degree underweight (%)), adverse effects
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Schaad 1989 (Continued)
Notes UoA issues - 42 participants received 56 courses of treatment
We shall seek to contact the study authors for IPD to include in a meta-analysis and
reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear - no detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical evaluation undertaken by 2 inves-
tigators without knowledge of allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Clinical outcomes available for about 50%
of participants only. Some participants are
young children (and so would be able to
perform lung function tests) but the mean
age is 15.4 years and so there are data miss-
ing for many participants for whom lung
function testing would have been possible
Selective reporting (reporting bias) Unclear risk Insufficient evidence.
Other bias High risk UoA issues - 42 participants received 56
courses of treatment
Semykin 2010
Methods RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: Russia.
Participants 108 participants with CF and chronic P. aeruginosa infection and acute pulmonary
exacerbations.
Intervention 1: 32 participants; age range 4 - 16 years.
Intervention 2: 39 participants; age range 6 - 17 years.
Intervention 3: 37 participants; age range 4 - 17 years.
Gender split not detailed.
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Semykin 2010 (Continued)
Interventions Intervention 1: inhaled tobramycin (TOBI or Bramitob) 300 mg 2x daily and IV cef-
tazidime (regimen not detailed) and oral ciprofloxacin (regimen not detailed)
Intervention 2: IV cefepime (regimen not detailed) and IV amikacin (regimen not de-
tailed)
Intervention 3: IV meropenem (regimen not detailed) and IV amikacin (regimen not
detailed)
Outcomes Lung function (FEV1, FVC), microbiology.
Notes Abstract only.
We shall contact the authors for more detail and data to allow contribution to a meta-
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No detail given.
Selective reporting (reporting bias) Unclear risk Insufficient detail.
Other bias Low risk None identified.
Smith 1999
Methods Double-blind RCT.
Parallel design.
Duration: 14 days.
Multicentre (9 centres).
Country: USA.
Participants 111 participants with CF experiencing a protocol-defined pulmonary exacerbation at
which time the predominant P. aeruginosamorphotype was susceptible to azlocillin and
tobramycin.
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Smith 1999 (Continued)
Intervention 1: 33 participants; mean (SD) age 16.07 (7.4) years; 19 males, 14 females
Intervention 2: 43 participants; mean (SD) age 16.53 (6.9) years; 18 males, 25 females
Interventions Intervention 1: IV azlocillin 450 mg/kg/day in 6 doses and placebo (5% dextrose) in 4
doses
Intervention 2:IV azlocillin 450 mg/kg/day in 6 doses and IV tobramycin 240 mg/m2/
day in 4 doses.
Outcomes Lung function (FEV1, FVC, PEFR, FRC, FEF25−75%), time to next exacerbation.
Notes 35 withdrawals are described.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by the core centre pharmacist
with a code generated at that centre
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as placebo-controlled double-
blind with unblinded third parties adjust-
ing tobramycin dosages and dummy ad-
justing placebo dosages by study pharma-
cist
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 35 withdrawals are described, although not
analysed as ITT.
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Unclear risk Funded by a grant fromMiles Pharmaceu-
ticals who manufactured azlocillin, how-
ever azlocillin not a comparator as both
study groups received azlocillin
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Stephens 1983
Methods RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: Canada.
Participants 28 participants with CF experiencing a pulmonary exacerbation
Intervention 1: 12 participants; mean (SD) age 15.1 (4.7) years; 9 males, 3 females
Intervention 2: 16 participants; mean (SD) age 15.3 (3.5) years; 9 males, 7 females
Interventions Intervention 1: IV tobramycin 10 mg/kg/day in 3 doses and IV ticarcillin 300 mg/kg/
day in 3 doses
Intervention 2: IV tobramycin 10 mg/kg/day in 3 doses and IV ticarcillin 300 mg/kg/
day in 3 doses and nebulised tobramycin 80 mg 3x daily
Outcomes Lung function (FEV1, FEV25−75%), weight, adverse effects.
Notes 3 participants were unable to be discharged at the end of treatment due to slow resolution
of symptoms, although it is unclear if these participants contributed to the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Technician performing lung function was
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 3 participants required a longer admission,
it is unclear if they contributed to the data
analysis
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias Low risk None identified.
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Wang 1988
Methods RCT.
Parallel design.
Duration: 2 weeks.
Single centre.
Country: USA
Participants 23 participants with CF experiencing pulmonary exacerbations
Age: over 18 years.
Gender split: no details given.
Interventions Intervention 1: oral ciprofloxacin 750 mg 2x daily.
Intervention 2: IV tobramycin and IV ticarcillin (dose not stated)
Intervention 3: IV tobramycin and IV azlocillin (dose not stated)
Outcomes Lung function (specific tests not stated), adverse effects, laboratory tests (blood counts,
blood chemistries, blood gases, sputum cultures), chest x-ray
Notes UoA issues - many participants received more than 1 treatment allocation
We shall seek to contact the study authors for IPD to include in a meta-analysis and
reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as random, but no detail given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No detail given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No detail given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No detail given.
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - many participants received
more than 1 treatment allocation
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Wesley 1988
Methods RCT.
Parallel design.
Duration: 14 days.
Single centre.
Country: New Zealand.
Participants 13 children with CF and severe chest disease.
Age range 9 - 15 years.
Gender split: not detailed.
Intervention 1: 13 participants.
Intervention 2: 10 participants.
Interventions Intervention 1: IV ceftazidime 150 mg/kg/day (regimen not detailed)
Intervention 2: IV tobramycin 7.5mg/kg/day and IV ticarcillin 300mg/kg/day (regimen
not detailed)
Outcomes Lung function (not detailed), adverse effects.
Notes UoA issues - 13 participants received 23 courses of treatment
We shall seek to contact the study authors for IPD to include in a meta-analysis and
reconcile the UoA issues
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no detail
given.
Allocation concealment (selection bias) Unclear risk No detail given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double blind but no detail
given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double blind but no detail
given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No detail available.
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - 13 participants received 23
courses of treatment
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Wientzen 1980
Methods Double-blind placebo-controlled RCT.
Parallel design.
Duration: not detailed.
Single centre.
Country: USA
Participants 22 participants with CF admitted to hospital due to an acute pulmonary exacerbation
Intervention 1: 12 participants; mean age (range) - 10.5 years (9 months - 27 years); 7
males, 5 females
Intervention 2: 12 participants; mean age (range) - 8.5 years (3 - 16 years); 6 males, 6
females
Interventions Intervention 1: IV tobramycin 2 mg/kg 3x daily.
Intervention 2: IV placebo (lactose solution).
Outcomes Lung function (FEV1, PEFR, VC), adverse effects, mortality.
Notes UoA issues - 2 participants treated 2x.
We shall contact the authors for data for inclusion in a meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a table of random numbers.
Allocation concealment (selection bias) Unclear risk Insufficient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind with adequate
evidence of blinding of participants and
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Adequate evidence of blinding of outcome
assessors.
Incomplete outcome data (attrition bias)
All outcomes
High risk Did not include participants whowithdrew
in the analysis. 2 participants died in the
placebo group (one onday 1 and the second
on day 4). Due to the small study size this
is surprising and so suggests either a failure
of random allocation or a difference in the
characteristics of the comparator groups at
baseline
Selective reporting (reporting bias) Unclear risk Insufficient information.
Other bias High risk UoA issues - 2 participants treated 2x.
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B. cepacia: Burkholderia cepacia
CF: cystic fibrosis
CI: confidence interval
CRP: C-reactive protein
FEV1: forced expiratory volume at one second
FEV25−75%: mid peak expiratory flow
FRC: functional residual capacity
FVC: forced vital capacity
IPD: individual patient data
ITT: intention to treat
IV: intravenous
P. aeruginosa: Pseudomonas aeruginosa
PEFR: peak expiratory flow rate
RCTL randomised controlled trial
RV: residual volume
SD: standard deviation
TLC: total lung capacity
TNF-α: tumour necrosis factor alpha
UoA: unit of analysis
VC: vital capacity
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aaron 2005 In vitro susceptibility testing trial.
Adeboyeku 2011 Dosing study.
Al-Ansari 2006 Dosing study.
Amelina 2000 Study of antibiotic location (home IVs).
Aminimanizani 2002 Dosing study.
Balsamo 1986 In vitro study.
Beringer 2003 Pharmacodynamics study.
Beringer 2010 Study of anti-inflammatory effect of doxycyline.
Brett 1992 Trial of chronic/maintenance therapy.
Burkhardt 2006 Dosing study.
Byrne 1995 Maintenance therapy, not exacerbation.
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(Continued)
Cabezudo 1984 Non-randomised, no comparison group.
Canis 1998 Dosing study.
Christensson 1992 Pharmacokinetic/pharmacodynamic study.
Conway 1996a Dosing study.
Davis 1987 Pharmacokinetic study.
Davis 1990 Study of antibiotic location (home vs hospital).
Day 1988 Comparison of inhaled therapies.
De Boeck 1998 Dosing study.
Degg 1996 Effect of antibiotics upon hearing (non-CF comparison group)
Dodge 1983 Observational study, no comparator.
Donati 1987 Non-randomised, study of antibiotic location (home vs hospital)
Elborn 2000 Study of antibiotic usage by indication (elective vs symptomatic)
Eron 1983 Randomised dosing study (multiple indications; not reported by indication)
Gold 1983 No comparator.
Goldfarb 1987 Single arm pharmacokinetic, toxicity and microbiology monitoring study
Guglielmo 1996 Dosing study.
Hamner 2006 Pharmacokinetic study, no comparator.
Hatziagorou 2013 Non-randomised observational study of lung clearance index.
Heaf 1984 Comparison of two inhaled regimens.
Heininger 1993 Once vs. thrice-daily study.
Hjelte 1988 Study of treatment location - home vs hospital study.
Hoogkamp-Korstanje 1983 Non-randomised study.
Hubert 2009 Dosing study.
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(Continued)
Ivanov 1997 Dosing study.
Jackson 1986 Non-randomised study.
Jacobs 1985 Pharmacokinetic study.
Jensen 1987 Study of maintenance/elective therapy.
Jewett 1985 Quasi-randomised by alternate participant selection.
Keel 2011 Pharmacokinetic study, not exacerbations.
Kercsmar 1983 Pharmacokinetic study, no comparator.
Klettke 1999 Study of antibiotic location (home vs hospital).
Krause 1979 Quasi-randomised as allocation by birth month.
Kruger 2001 Dosing study.
Kuni 1992 Non-randomised, no comparator, deposition study.
Kuzemko 1989 Dosing study.
Labiris 2004 Toxicity study, no comparator.
Levy 1982 No comparison group.
Levy 1982a Non-randomised study.
Li 1991 Computerised dosing study.
Martin 1980 Non-randomised study.
McCabe 2013 Dosing study - twice vs thrice daily tobramycin.
Michalsen 1981 Non-randomised study.
Moss 1991 Immunology/desensitisation study.
Mouton 1991 Dosing study.
Nikolaizik 2005 Dosing study.
Nikonova 2010 Inhaled medications only.
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(Continued)
Padoan 1988 Dosing study.
Parry 1977 Non-randomised study.
Pedersen 1986 Maintenance therapy, not exacerbation.
Permin 1983 Maintenance therapy, not exacerbation.
Popa 2001 Non-randomised study.
Postnikov 2001 Non-randomised study.
Postnikov 2001a Non-randomised study.
Postnikov 2007 Dosing study.
Powell 1983 Dosing study.
Prayle 2013 Pharmacokinetic study only.
Ramstrom 2000 Trial of drug preparation (patient vs pharmacist).
Reed 1987 Reports an open, uncontrolled study and a randomised study of dosing
Reed 1987a Dosing study.
Riethmueller 2009 Dosing study.
Roberts 1992 Pharmacokinetic study.
Rubio 1987 Non-randomised study.
Shatunov 2001 Non-randomised.
Smyth 2005 Dosing study.
Turner 2013 Dosing study - continuous vs intermittent dosing regimens.
Wainwright 2011 Trial of bronchoscopy-guided antibiotic therapy.
Whitehead 2002 Dosing study.
Winnie 1991 Dosing study.
Wolter 1997 Study of antibiotic location (home vs hospital).
Wood 1996 Dosing study.
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Yasmin 1974 Maintenance therapy, not exacerbations.
CF: cystic fibrosis
IVs: intravenous antibiotics
vs: versus
Characteristics of studies awaiting assessment [ordered by study ID]
Al-Aloul 2005
Methods Cross-over RCT comparing intravenous and nebulised tobramycin
Participants 13 or 14 adults with CF and chronically infected with Liverpool epidemic strain P. aeruginosa.
Age: mean (SD) 22 (7) years.
Disease severity: mean (SD) FEV1 % predicted 65 (22).
Interventions Participants were randomised to receive, either nebulised or IV antibiotics during consecutive exacerbations over four
successive exacerbations (mean (SD) interval between exacerbations was 7.8 (5.5) months)
Intervention 1: TOBI (nebulised tobramycin) 300 mg 2x daily.
Intervention 2: IV tobramycin (mean daily dose 8.2 mg/kg in 2 or 3 divided doses)
In both arms IV colomycin 2 megaunits 3x daily was also given
Outcomes Lung function, quantitative microbiology and renal toxicity adverse effects
Notes 2 references appear to report data from the same study. Both reports have the same mean and SD values for FEV1,
BMI and mean daily dose of tobramycin. The 2005 report is noted to include 13 participants and the 2004 report
noted to include 14 participants. Due to all other similarities we have considered the reports to be two from the same
study
We shall seek to contact the authors to request data for the first treatment allocation for each participant
Beaudry 1980
Methods RCT.
Participants Children with severe CF and signs of acute infection.
Interventions Cloxacillin or carbenicillin plus gentamicin administered intravenously for 10 days
Outcomes Clinical improvement, radiology.
Notes We shall seek to contact the authors for data relating to outcomes includable in the review
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Crawley 2005
Methods Unclear if randomised.
Participants Unclear number of participants included.
Interventions Subcutaneous infusions of either meropenem or ceftazidime (plus TOBI in 3 cases)
Outcomes Lung function, adverse effects.
Notes We shall seek to contact the authors for details of study design and individual participant data
Dinwiddie 1982
Methods Cross-over RCT.
Participants 9 children with chronic P. aeruginosa infection.
Interventions 14 days treatment with IV azlocillin or IV gentamicin.
Outcomes Lung function, weight, adverse effects.
Notes We shall seek to contact the authors for individual participant data in order to determine the first treatment episode
for each participant
Döring 1995
Methods Double-blind, placebo-controlled cross-over trial.
Participants 10 participants with P. aeruginosa infection.
Interventions Individualised IV antibiotic (not detailed) therapy versus placebo for 2 weeks
Outcomes Lung function, immunology.
Notes No data in the abstract - we shall seek to contact the authors for individual participant data to include the 1st
treatment event data in the analysis
Geborek 2003
Methods Open cross-over RCT.
Participants Unstated number of participants with chronic P. aeruginosa infection, experiencing an exacerbation.
Interventions Nebulised TOBI and an IV ß-lactam versus IV tobramycin and a ß-lactam for 10 days
Outcomes Lung function, adverse effects, time to next exacerbation.
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Geborek 2003 (Continued)
Notes We shall seek to contact the authors for individual participant data in order to use the 1st episode for each participant
in the meta-analysis
There also appears to be some typographical errors in the data table and so shall clarify the correct data
Harris 1984
Methods Methods not clear.
Duration: 10 - 14 days.
Participants Participants with CF.
Interventions IV antibiotics and aggressive pulmonary treatment.
Outcomes Pulmonary function, PWC, and VO2max.
Notes
Huang 1979
Methods Double-blind study (part placebo-controlled) not clear if randomised
Duration: 10 days.
Participants 25 participants experiencing an acute exacerbation.
Interventions Intervention 1: IV ticarcillin 300 mg/kg/day or placebo.
Intervention 2: IV ticarcillin 300 mg/kg/day and IV tobramycin 6 mg/kg/day
Intervention 3: IV carbenicillin 500 mg/kg/day and IV tobramycin 6 mg/kg/day
Outcomes Scoring system (including lung function, and clinical assessment), time to next exacerbation and microbiology
Notes Difficulty in obtaining informed consent to study with placebo arm (3 participants recruited to this arm) and so
placebo group was replaced with ticarcillin group
25 participants contributed 29 treatment episodes.
We shall seek to contact the authors for clarification of randomisation and for IPD to contribute to a meta-analysis
and resolve the UoA issues
Kapranov 1995
Methods Unclear if randomised.
Participants 41 participants with CF with severe or very severe disease aged 3 - 16 years
Interventions Ciprofloxacin (n = 31) versus ofloxacin (n = 9).
Outcomes “Clinical remission” and side effects.
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Kapranov 1995 (Continued)
Notes Unclear if symptomatic or elective treatment.
We plan to contact authors to clarify randomisation. Given the imbalance in number of participants receiving each
intervention, this is probably not a randomised trial
Latzin 2008
Methods Open-label RCT for 3 indications:
(1) suppression therapy for those with chronic P. aeruginosa not experiencing an exacerbation;
(2) acute exacerbation in those with chronic P. aeruginosa infection; and
(3) eradication of first detection of P. aeruginosa infection.
Participants 127 participants enrolled, of whom34were recruited as they had chronicP. aeruginosa infection andwere experiencing
an acute exacerbation.
Interventions Intervention 1: IV meropenem 120 mg/kg/day in 3 doses and IV tobramycin 9 - 12 mg/kg/day in 2 doses
Intervention 2: IV ceftazidime 200 - 400 mg/kg/day in 2 or 3 doses and tobramycin 9 - 12 mg/kg/day in 2 doses
Outcomes Lung function, adverse effects, microbiology.
Notes While a subgroup analysis consisting of the 3 indications is described for lung function, data are presented as a whole
Participants could be recruited 2x although this is not described
We shall seek to contact the authors for IPD to reconcile the UoA issues and for data to contribute to a meta-analysis
Parry 1978
Methods RCT.
Duration: a minimum of 10 days.
Participants 88 participants of whom 51 had CF.
Interventions Intervention 1: IV ticarcillin 300 mg/kg/day and IV tobramycin 4.5 mg/kg/day
Intervention 2: IV carbenicillin 450 mg/kg/day and IV gentamicin 4.5 mg/kg/day
Outcomes Lung function, clinical score, microbiology, adverse effects
Notes A pooled analysis is presented combining treatment for all indications
We shall seek to contact the authors for IPD for those with CF to contribute to a meta-analysis
Vic 1997
Methods Comparison study - unclear if randomised.
Duration: 14 days.
Participants 38 participants with chronic P. aeruginosa infection presenting with a protocol-defined pulmonary exacerbation
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Vic 1997 (Continued)
Interventions Intervention 1: IV ceftazidime 200 mg/kg/day and IV amikacin 35 mg/kg/day
Intervention 2: IV ceftazidime 200 mg/kg/day and IV tobramycin 15 mg/kg/day
Outcomes Nutritional status.
Notes Need to clarify if randomised.
% predicted: per cent of lung function measure compared to someone of the same age, height and ethnicity
BMI: body mass index
CF: cystic fibrosis
CI: confidence intervals
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
IPD: individual patient data
IV: intravenous
P. aeruginosa: Pseudomonas aeruginosa
PEFR: peak expiratory flow rate
PWC: physical work capacity
RCT: randomised controlled trial
SD: standard deviation
UoA: unit of analysis
VO2max : maximum volume of oxygen
WBC: white blood cell
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D A T A A N D A N A L Y S E S
Comparison 1. Single IV antibiotic versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FVC % predicted (relative
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Ceftazidime 200 mg/kg/
day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Weight (relative change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Ceftazidime 200 mg/kg/
day
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Combination IV antibiotic versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Ticarcillin and tobramycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Ticarcillin and tobramycin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Single IV agents compared
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ceftazidime versus aztreonam 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 FEV1 litres (absolute
change)
2 46 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-1.08, 0.84]
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Comparison 4. Single IV antibiotic (with placebo) versus combination IV antibiotic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change)
4 214 Mean Difference (IV, Fixed, 95% CI) -0.89 [-3.14, 1.36]
1.1 Azlocillin & placebo
versus azlocillin & tobramycin
2 93 Mean Difference (IV, Fixed, 95% CI) 1.37 [-1.50, 4.23]
1.2 Oxacillin & placebo
versus oxacillin & sisomycin &
carbenicillin
1 23 Mean Difference (IV, Fixed, 95% CI) -9.54 [-15.98, -3.10]
1.3 Tobramycin & placebo
versus tobramycin &
ceftazidime
1 98 Mean Difference (IV, Fixed, 95% CI) -2.20 [-6.63, 2.23]
2 FEV1 % predicted (relative
change)
1 18 Mean Difference (IV, Fixed, 95% CI) 3.58 [-9.80, 16.96]
2.1 Tobramycin & placebo
versus piperacillin 50 mg/kg
(6x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -4.20 [-26.50, 18.
10]
2.2 Tobramycin & placebo
versus piperacillin 100 mg/kg
(3x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) 7.95 [-8.78, 24.68]
3 FVC % predicted (absolute
change)
3 116 Mean Difference (IV, Fixed, 95% CI) 0.02 [-3.48, 3.52]
3.1 Azlocillin & placebo
versus azlocillin & tobramycin
2 93 Mean Difference (IV, Fixed, 95% CI) 1.18 [-2.53, 4.89]
3.2 Oxacillin & placebo
versus oxacillin & sisomycin &
carbenicillin
1 23 Mean Difference (IV, Fixed, 95% CI) -9.32 [-19.86, 1.22]
4 FVC % predicted (relative
change)
1 18 Mean Difference (IV, Fixed, 95% CI) -1.26 [-12.40, 9.88]
4.1 Tobramycin & placebo
versus piperacillin 50mg/kg (6x
daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -1.20 [-15.79, 13.
39]
4.2 Tobramycin & placebo
versus piperacillin 100 mg/kg
(3x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -1.35 [-18.61, 15.
91]
5 Time to next exacerbation
(weeks)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Azlocillin & placebo
versus azlocillin & tobramycin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Weight (absolute change (kg)) 1 18 Mean Difference (IV, Fixed, 95% CI) -0.36 [-1.66, 0.93]
6.1 Tobramycin & placebo
versus piperacillin 50mg/kg (6x
daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -0.72 [-2.65, 1.21]
6.2 Tobramycin & placebo
versus piperacillin 100mg/kg
(3x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -0.07 [-1.83, 1.69]
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7 Adverse effects - sensitivity
reaction
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Piperacillin (all regimens) 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Adverse effects 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 All adverse effects 2 145 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.50, 2.37]
8.2 Ototoxicity 2 88 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Nephrotoxocity 2 104 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.05, 7.27]
8.4 Proteinuria 1 63 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.02, 1.89]
8.5 Infusion site irritation 1 111 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [0.26, 10.08]
8.6 Tinnitus 1 98 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.15, 8.06]
9 Adverse effects - serum 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Creatinine 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 NAG 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Single IV antibiotic versus combination IV antibiotic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 ml (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Colstin versus colistin &
“other”
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FEV1 % predicted (absolute
change)
2 51 Mean Difference (IV, Fixed, 95% CI) -2.73 [-8.42, 2.95]
2.1 Aztreonam versus
tobramycin & azlocillin
1 30 Mean Difference (IV, Fixed, 95% CI) -4.60 [-11.57, 2.37]
2.2 Ceftazidime versus
tobramycin & piperacillin
1 21 Mean Difference (IV, Fixed, 95% CI) 1.0 [-8.85, 10.85]
3 FEV1 % (relative change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Ceftazidime versus
tobramycin & ticarcillin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FEV1 (all measures) 3 122 Std. Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.74, -0.02]
4.1 Aztreonam versus
tobramycin & azlocillin
1 30 Std. Mean Difference (IV, Fixed, 95% CI) -0.46 [-1.19, 0.27]
4.2 Ceftazidime versus
tobramycin & piperacillin
1 21 Std. Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.77, 0.94]
4.3 Colstin versus colistin &
“other”
1 71 Std. Mean Difference (IV, Fixed, 95% CI) -0.49 [-0.96, -0.02]
5 FVC ml (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Colstin versus colistin &
“other”
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Aztreonam versus
azlocillin & tobramycin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 FVC % predicted (relative
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Aztreonam versus
azlocillin & tobramycin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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8 FVC (all measures) 2 101 Std. Mean Difference (IV, Fixed, 95% CI) -0.89 [-1.30, -0.48]
8.1 Colstin versus colistin &
“other”
1 71 Std. Mean Difference (IV, Fixed, 95% CI) -0.96 [-1.45, -0.46]
8.2 Aztreonam versus
azlocillin & tobramycin
1 30 Std. Mean Difference (IV, Fixed, 95% CI) -0.73 [-1.48, 0.01]
9 Time to readmission (months) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Ceftazidime versus
tobramycin & piperacillin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Proportion readmitted,
requiring IV antibiotics or
death in subsequent 3 months
2 104 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.19, 0.95]
10.1 Ceftazidime versus
carbenicillin & gentamicin
1 82 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.12, 0.74]
10.2 Ceftazidime versus
tobramycin & ticarcillin
1 22 Odds Ratio (M-H, Fixed, 95% CI) 1.4 [0.26, 7.58]
11 Weight (% change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Ceftazidime versus
tobramycin & ticarcillin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Mortality 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.09, 4.37]
12.1 Ceftazidime versus
tobramycin & ticarcillin
1 21 Risk Ratio (M-H, Fixed, 95% CI) 1.1 [0.08, 15.36]
12.2 Colstin versus colistin &
“other”
1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.70]
12.3 Piperacillin versus
piperacillin & tobramycin
1 17 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Adverse effects 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Liver transaminase
enzyme elevation
4 164 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.58, 2.86]
13.2 Neurological adverse
effects
1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 3.96]
13.3 Rash 3 129 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.24, 5.48]
13.4 Thrombophlebitis 1 82 Odds Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 1.21]
13.5 Fever 1 17 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.06, 21.87]
13.6 Proteinuria 1 34 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 17.41]
14 Renal toxicity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Change in blood urea
(mmol/l)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 Change in serum
creatinine (mol/l)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Antibiotic resistance - number
of participants isolating
resistant strains
4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 All antibiotics 3 107 Odds Ratio (M-H, Fixed, 95% CI) 0.42 [0.14, 1.24]
15.2 Ceftazidime versus
gentamicin
1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.08, 3.38]
15.3 Ceftazidime versus
carbenicillin
1 61 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.07, 3.00]
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Comparison 6. Single versus combination
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 (all measures) 7 336 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.42, 0.01]
1.1 Single antibiotic with
placebo versus combination
regimen
4 214 Std. Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.38, 0.17]
1.2 Single antibiotic (no
placebo) versus combination
regimen
3 122 Std. Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.74, -0.02]
2 FEV1 ml (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Colstin versus colistin &
“other”
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 FEV1 % predicted (absolute
change)
6 265 Mean Difference (IV, Fixed, 95% CI) -1.14 [-3.23, 0.95]
3.1 Azlocillin & placebo
versus azlocillin & tobramycin
2 93 Mean Difference (IV, Fixed, 95% CI) 1.37 [-1.50, 4.23]
3.2 Aztreonam versus
tobramycin & azlocillin
1 30 Mean Difference (IV, Fixed, 95% CI) -4.60 [-11.57, 2.37]
3.3 Tobramycin & placebo
versus tobramycin &
ceftazidime
1 98 Mean Difference (IV, Fixed, 95% CI) -2.20 [-6.63, 2.23]
3.4 Oxacillin & placebo
versus oxacillin & sisomycin &
carbenicillin
1 23 Mean Difference (IV, Fixed, 95% CI) -9.54 [-15.98, -3.10]
3.5 Ceftazidime versus
tobramycin & piperacillin
1 21 Mean Difference (IV, Fixed, 95% CI) 1.0 [-8.85, 10.85]
4 FEV1 litres (relative change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Ceftazidime versus
tobramycin & ticarcillin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 FEV1% predicted (relative
change)
1 18 Mean Difference (IV, Fixed, 95% CI) 3.58 [-9.80, 16.96]
5.1 Tobramycin & placebo
versus piperacillin 50 mg/kg
(6x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -4.20 [-26.50, 18.
10]
5.2 Tobramycin & placebo
versus piperacillin 100 mg/kg
(3x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) 7.95 [-8.78, 24.68]
6 FVC (all measures) 5 217 Std. Mean Difference (IV, Fixed, 95% CI) -0.44 [-0.71, -0.16]
6.1 Single antibiotic with
placebo versus combination
regimen
3 116 Std. Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.43, 0.31]
6.2 Single antibiotic (no
placebo) versus combination
regimen
2 101 Std. Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.31, -0.49]
7 FVC % predicted (absolute
change)
4 146 Mean Difference (IV, Fixed, 95% CI) -1.37 [-4.56, 1.81]
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7.1 Azlocillin & placebo
versus azlocillin & tobramycin
2 93 Mean Difference (IV, Fixed, 95% CI) 1.18 [-2.53, 4.89]
7.2 Oxacillin & placebo
versus oxacillin & sisomycin &
carbenicillin
1 23 Mean Difference (IV, Fixed, 95% CI) -9.32 [-19.86, 1.22]
7.3 Aztreonam versus
azlocillin & tobramycin
1 30 Mean Difference (IV, Fixed, 95% CI) -8.1 [-15.79, -0.41]
8 FVC % predicted (relative
change)
2 48 Mean Difference (IV, Fixed, 95% CI) -6.60 [-13.99, 0.79]
8.1 Tobramycin & placebo
versus piperacillin 50mg/kg (6x
daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -1.20 [-15.79, 13.
39]
8.2 Tobramycin & placebo
versus piperacillin 100 mg/kg
(3x daily) & tobramycin
1 9 Mean Difference (IV, Fixed, 95% CI) -1.35 [-18.61, 15.
91]
8.3 Aztreonam versus
azlocillin & tobramycin
1 30 Mean Difference (IV, Fixed, 95% CI) -10.80 [-20.67, -0.
93]
9 FVC ml (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Colstin versus colistin &
“other”
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. IV meropenem & IV tobramycin versus IV ceftazidime & IV tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 14 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FEV1 % predicted (relative %
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 14 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Participants experiencing an
exacerbation
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 At up to 1 month 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Antibiotic resistance 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 At up to 1 month 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 8. IV ticarcillin & IV tobramycin versus IV azlocillin & IV tobramycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 10 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Time to next exacerbation
(weeks)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Antibiotic resistance 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 At 4 weeks after end of
treatment
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 9. IV azlocillin & IV gentamicin versus IV carbenicillin & IV gentamicin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 ml (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 10 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC ml (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 10 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 During treatment up to
10 days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 12-month follow up 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 During treatment 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 10. IV netilmicin & IV azlocillin versus IV netilmicin & IV ticarcillin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 10 to 17 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Liver transaminase
elevation
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse effects- antibiotic
resistance
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Azlocillin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Ticarcillin 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 11. IV aztreonam & IV amikacin versus IV ceftazidime & IV amikacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Thrombocytopenia 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Liver transaminases -
AST/SGOT& ALT/SGPT
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Rash 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. IV ceftazidime & IV amikacin versus IV ceftazidime & IV amikacin & inhaled amikacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Raised liver transaminases 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 13. IV azlocillin & IV tobramycin versus oral ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 14 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 14 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 14. IV azlocillin & IV gentamicin versus oral ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 litres (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 10 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FVC litres (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 10 days 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Six weeks 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Three months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 15. IV ceftazidime & IV tobramycin versus oral ciprofloxacin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion experiencing
exacerbation 9-30 days post-
treatment
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Treatment-related events 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 16. IV versus oral antibiotics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 2 64 Std. Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.73, 0.25]
2 FVC 2 64 Std. Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.74, 0.26]
3 FEV1 litres (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 IV azlocillin & IV
gentamicin versus oral
ciprofloxacin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FEV1 % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 IV azlocillin & IV
tobramycin versus oral
ciprofloxacin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 FVC litres (absolute change) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 IV azlocillin & IV
gentamicin versus oral
ciprofloxacin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FVC % predicted (absolute
change)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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6.1 IV azlocillin & IV
tobramycin versus oral
ciprofloxacin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Comparison of single antibiotics - adverse effects
Agostini 1983 Adverse effect Azlocillin
n = 16
Piperacillin
n = 23
Ceftazidime
n = 28
Cefsulodin
n = 19
Cefoperazone
n = 15
Reported symp-
toms
Fever 3.6% 18.7% 0% 2.6% 0%
Rash 3.6% 12.5% 0% 10.3% 3.8%
Itching 0% 3.1% 05 3.4% 0%
Nausea&vomit-
ing
0% 3.1% 3.1% 34.5% 0%
Diarrhoea 3.6% 0% 0% 10.3% 26.9%
Vertigo 0% 3.1% 0%% 0% 0%
Laboratory find-
ings
Raised AST
(SGOT)
0% 12.5% 9.3% 6.8% 3.8%
Raised ALT
(SGPT)
3.65 21.8% 15.6% 20.7% 7.7%
Leucopenia 0% 6.2% 3.1% 0% 0%
Eosinophilia 28.6% 34.4% 43.7% 20.7% 26.9%
Bleeding time
increased
05 6.2% 0% 0% 0%
Proteinuria 0% 0% 0% 0% 0%
Haematuria 7.1% 9.4% 0% 0% 0%
LAD 5th 7.1% 0% 6.0% 13.0% 7.0%
New bacterial
species emerging
after treatment
Achromobacter
species
0 0 2 0 0
Candida species 1 1 3 2 2
Enterobacter
species
3 3 0 0 1
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Table 1. Comparison of single antibiotics - adverse effects (Continued)
Haemophilus
species
2 2 0 1 0
Pseudomonas al-
caligenes
0 0 1 0 0
Pseudomonas
maltophilia
1 0 3 0 0
Staphylococcus
species
2 3 0 0 0
ALT: alanine aminotransferase
AST: aspartate aminotransferase
SGOT: serum glutamic-oxaloacetic transaminase
SGPT: serum glutamic-pyruvic transaminase
Table 2. Data from Mastella 1983
Feature Azlocillin
(%)
Piperacillin
(%)
Ceftazidime
(%)
Cefsulodin
(%)
Cefoperazone
(%)
Fever 2.5 18.7 5.5
Rash 2.5 12.5 5.5 3
Itching 3.1 2.7
N&V 3.1 3.1 30.5
Diarrhoea 2.5 8.3 24.2
Vertigo 3.1
N&V: nausea and vomiting
Table 3. IV ceftazidime alone versus combination IV ceftazidime & IV sisomycin versus combination IV piperacillin & IV
sisomycin: Adverse events
Padoan 1987 Ceftazidime Ceftazidime & sisomycin Piperacillin & sisomycin
Adverse effect
Eosinophilia 8/40 2/20
Raised liver enzymes 20% 20% 20%
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Table 3. IV ceftazidime alone versus combination IV ceftazidime & IV sisomycin versus combination IV piperacillin & IV
sisomycin: Adverse events (Continued)
Fever 7/20
Renal impairment 0 0 0
Antibiotic resistance to agents
at end of treatment
30% 37% & 40% 40% & 32%
WH A T ’ S N E W
Last assessed as up-to-date: 27 July 2015.
Date Event Description
29 June 2017 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 3, 2012
Review first published: Issue 7, 2015
Date Event Description
9 September 2015 Amended Grade added to summary of finding table ’Single versus combination IV antibiotics’
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol MH, AP, PF
Review stage: select which trials to include (2 + 1 arbiter) MH, AP, PF
Review stage: extract data from trials (2 people) MH, AP
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(Continued)
Review stage: enter data into RevMan MH
Review stage: carry out the analysis MH
Review stage: interpret the analysis MH
Review stage: draft the final review MH with comments from PF & AP
Update stage: update the review MH, AP, PF
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a post hoc change, we decided to exclude any studies that exclusively compared different doses of the same antibiotic.
In a further post hoc change, we have presented summary of findings tables for single versus combination intravenous antibiotics, for
oral versus intravenous antibiotics and for nebulised versus intravenous antibiotics.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗administration&dosage; adverse effects]; Cystic Fibrosis [∗drug therapy; physiopathology];Disease Progression;
Injections, Intravenous; Total Lung Capacity [physiology]
MeSH check words
Adolescent; Adult; Child; Humans
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